cached image

Philip Scheltens, MD PhD - Publications

Affiliations: 
Alzheimer Center VU University Medical Center, Amsterdam, Netherlands 
Area:
dementia, MRI, CSF, PET, http://www.researchprofiles.collexis.com/jad/expert.asp?u_id=111
Website:
https://www.knaw.nl/nl/leden/leden/11669

500 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Briels CT, Eertink JJ, Stam CJ, van der Flier WM, Scheltens P, Gouw AA. Profound regional spectral, connectivity, and network changes reflect visual deficits in posterior cortical atrophy: an EEG study. Neurobiology of Aging. 96: 1-11. PMID 32905950 DOI: 10.1016/j.neurobiolaging.2020.07.029  0.84
2020 Legdeur N, Badissi M, Yaqub M, Beker N, Sudre CH, Ten Kate M, Gordon MF, Novak G, Barkhof F, van Berckel BNM, Holstege H, Muller M, Scheltens P, Maier AB, Visser PJ. What determines cognitive functioning in the oldest-old? The EMIF-AD 90+ Study. The Journals of Gerontology. Series B, Psychological Sciences and Social Sciences. PMID 32898275 DOI: 10.1093/geronb/gbaa152  1
2020 de Leeuw FA, Karamujić-Čomić H, Tijms BM, Peeters CFW, Kester MI, Scheltens P, Ahmad S, Vojinovic D, Adams HHH, Hankemeier T, Bos D, van der Lugt A, Vernooij MW, Ikram MA, Amin N, et al. Circulating metabolites are associated with brain atrophy and white matter hyperintensities. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 32886448 DOI: 10.1002/alz.12180  1
2020 Rhodius-Meester HFM, Paajanen T, Koikkalainen J, Mahdiani S, Bruun M, Baroni M, Lemstra AW, Scheltens P, Herukka SK, Pikkarainen M, Hall A, Hänninen T, Ngandu T, Kivipelto M, van Gils M, et al. cCOG: A web-based cognitive test tool for detecting neurodegenerative disorders. Alzheimer's & Dementia (Amsterdam, Netherlands). 12: e12083. PMID 32864411 DOI: 10.1002/dad2.12083  0.84
2020 Shi L, Winchester LM, Liu BY, Killick R, Ribe EM, Westwood S, Baird AL, Buckley NJ, Hong S, Dobricic V, Kilpert F, Franke A, Kiddle S, Sattlecker M, Dobson R, ... ... Scheltens P, et al. Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. Journal of Alzheimer's Disease : Jad. PMID 32831200 DOI: 10.3233/JAD-200208  1
2020 Ulugut Erkoyun H, Groot C, Heilbron R, Nelissen A, van Rossum J, Jutten R, Koene T, van der Flier WM, Wattjes MP, Scheltens P, Ossenkoppele R, Barkhof F, Pijnenburg Y. A clinical-radiological framework of the right temporal variant of frontotemporal dementia. Brain : a Journal of Neurology. PMID 32830218 DOI: 10.1093/brain/awaa225  1
2020 Frisoni GB, Molinuevo JL, Altomare D, Carrera E, Barkhof F, Berkhof J, Delrieu J, Dubois B, Kivipelto M, Nordberg A, Schott JM, van der Flier WM, Vellas B, Jessen F, Scheltens P, et al. Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 32815289 DOI: 10.1002/alz.12132  1
2020 Verhaar BJH, de Leeuw FA, Doorduijn AS, Fieldhouse JLP, van de Rest O, Teunissen CE, van Berckel BNM, Barkhof F, Visser M, de van der Schueren MAE, Scheltens P, Kester MI, Muller M, van der Flier WM. Nutritional status and structural brain changes in Alzheimer's disease: The NUDAD project. Alzheimer's & Dementia (Amsterdam, Netherlands). 12: e12063. PMID 32793798 DOI: 10.1002/dad2.12063  1
2020 Mok VCT, Pendlebury S, Wong A, Alladi S, Au L, Bath PM, Biessels GJ, Chen C, Cordonnier C, Dichgans M, Dominguez J, Gorelick PB, Kim S, Kwok T, Greenberg SM, ... ... Scheltens P, et al. Tackling challenges in care of Alzheimer's disease and other dementias amid the COVID-19 pandemic, now and in the future. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 32789951 DOI: 10.1002/alz.12143  0.4
2020 Boomsma JMF, Exalto LG, Barkhof F, Chen CLH, Hilal S, Leeuwis AE, Prins ND, Saridin FN, Scheltens P, Teunissen CE, Verwer JH, Weinstein HC, van der Flier WM, Biessels GJ. Prediction of poor clinical outcome in vascular cognitive impairment: TRACE-VCI study. Alzheimer's & Dementia (Amsterdam, Netherlands). 12: e12077. PMID 32789162 DOI: 10.1002/dad2.12077  1
2020 Mofrad RB, Tijms BM, Scheltens P, Barkhof F, van der Flier WM, Am Sikkes S, Teunissen CE. Sex differences in CSF biomarkers vary by Alzheimer's disease stage and APOE ε4 genotype. Neurology. PMID 32788242 DOI: 10.1212/WNL.0000000000010629  1
2020 Heinen R, Groeneveld ON, Barkhof F, de Bresser J, Exalto LG, Kuijf HJ, Prins ND, Scheltens P, van der Flier WM, Biessels GJ. Small vessel disease lesion type and brain atrophy: The role of co-occurring amyloid. Alzheimer's & Dementia (Amsterdam, Netherlands). 12: e12060. PMID 32695872 DOI: 10.1002/dad2.12060  1
2020 Collij LE, Heeman F, Salvadó G, Ingala S, Altomare D, Wilde A, Konijnenberg E, van Buchem M, Yaqub M, Markiewicz P, Golla SSV, Wottschel V, Wink AM, Visser PJ, Teunissen CE, ... ... Scheltens P, et al. Multi-tracer model for staging cortical amyloid deposition using PET imaging. Neurology. PMID 32675080 DOI: 10.1212/WNL.0000000000010256  0.84
2020 Groot C, Yeo BTT, Vogel JW, Zhang X, Sun N, Mormino EC, Pijnenburg YAL, Miller BL, Rosen HJ, Joie R, Barkhof F, Scheltens P, van der Flier WM, Rabinovici GD, Ossenkoppele R. Latent atrophy factors related to phenotypical variants of posterior cortical atrophy. Neurology. PMID 32675078 DOI: 10.1212/WNL.0000000000010362  1
2020 de Leeuw FA, van de Rest O, Doorduijn AS, Fieldhouse JLP, de van der Schueren MAE, Visser M, van den Heuvel EGHM, Scheltens P, Teunissen CE, Kester MI, van der Flier WM. Associations Between Nutrient Intake and Corresponding Nutritional Biomarker Levels in Blood in a Memory Clinic Cohort: The NUDAD Project. Journal of the American Medical Directors Association. PMID 32641272 DOI: 10.1016/j.jamda.2020.04.031  0.84
2020 Joanne van der Zande J, Gouw AA, van Steenoven I, van de Beek M, Scheltens P, Stam CJ, Lemstra AW. Diagnostic and prognostic value of EEG in prodromal dementia with Lewy bodies. Neurology. PMID 32636325 DOI: 10.1212/WNL.0000000000009977  0.8
2020 Muurling M, Rhodius-Meester HFM, Pärkkä J, van Gils M, Frederiksen KS, Bruun M, Hasselbalch SG, Soininen H, Herukka SK, Hallikainen M, Teunissen CE, Visser PJ, Scheltens P, van der Flier WM, Mattila J, et al. Gait Disturbances are Associated with Increased Cognitive Impairment and Cerebrospinal Fluid Tau Levels in a Memory Clinic Cohort. Journal of Alzheimer's Disease : Jad. PMID 32597806 DOI: 10.3233/JAD-200225  0.84
2020 Dicks E, van der Flier WM, Scheltens P, Barkhof F, Tijms BM. Single-subject gray matter networks predict future cortical atrophy in preclinical Alzheimer's disease. Neurobiology of Aging. 94: 71-80. PMID 32585492 DOI: 10.1016/j.neurobiolaging.2020.05.008  1
2020 de Vos F, Schouten TM, Koini M, Bouts MJRJ, Feis RA, Lechner A, Schmidt R, van Buchem MA, Verhey FRJ, Olde Rikkert MGM, Scheltens P, de Rooij M, van der Grond J, Rombouts SARB. Pre-trained MRI-based Alzheimer's disease classification models to classify memory clinic patients. Neuroimage. Clinical. 27: 102303. PMID 32554321 DOI: 10.1016/j.nicl.2020.102303  0.64
2020 Staekenborg SS, Kelly N, Schuur J, Koster P, Scherder E, Tielkes CEM, Scheltens P, Claus JJ. Education as Proxy for Cognitive Reserve in a Large Elderly Memory Clinic: 'Window of Benefit'. Journal of Alzheimer's Disease : Jad. PMID 32538838 DOI: 10.3233/JAD-191332  0.76
2020 Ebenau JL, Timmers T, Wesselman LMP, Verberk IMW, Verfaillie SCJ, Slot RER, van Harten AC, Teunissen CE, Barkhof F, van den Bosch KA, van Leeuwenstijn M, Tomassen J, Braber AD, Visser PJ, Prins ND, ... ... Scheltens P, et al. ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project. Neurology. PMID 32522798 DOI: 10.1212/WNL.0000000000009724  1
2020 Briels CT, Schoonhoven DN, Stam CJ, de Waal H, Scheltens P, Gouw AA. Reproducibility of EEG functional connectivity in Alzheimer's disease. Alzheimer's Research & Therapy. 12: 68. PMID 32493476 DOI: 10.1186/s13195-020-00632-3  0.8
2020 Visser D, Wolters EE, Verfaillie SCJ, Coomans EM, Timmers T, Tuncel H, Reimand J, Boellaard R, Windhorst AD, Scheltens P, van der Flier WM, Ossenkoppele R, van Berckel BNM. Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging. PMID 32462397 DOI: 10.1007/s00259-020-04831-w  0.84
2020 Konijnenberg E, Tijms BM, Gobom J, Dobricic V, Bos I, Vos S, Tsolaki M, Verhey F, Popp J, Martinez-Lage P, Vandenberghe R, Lleó A, Frölich L, Lovestone S, Streffer J, ... ... Scheltens P, et al. APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease. Alzheimer's Research & Therapy. 12: 65. PMID 32460813 DOI: 10.1186/s13195-020-00628-z  0.76
2020 Biessels GJ, Nobili F, Teunissen CE, Simó R, Scheltens P. Understanding multifactorial brain changes in type 2 diabetes: a biomarker perspective. The Lancet. Neurology. PMID 32445622 DOI: 10.1016/S1474-4422(20)30139-3  0.72
2020 Ahmad S, Milan MDC, Hansson O, Demirkan A, Agustin R, Sáez ME, Giagtzoglou N, Cabrera-Socorro A, Bakker MHM, Ramirez A, Hankemeier T, Stomrud E, Mattsson-Carlgren N, Scheltens P, van der Flier WM, et al. CDH6 and HAGH protein levels in plasma associate with Alzheimer's disease in APOE ε4 carriers. Scientific Reports. 10: 8233. PMID 32427856 DOI: 10.1038/s41598-020-65038-5  0.84
2020 Dubbelman MA, Verrijp M, Facal D, Sánchez-Benavides G, Brown LJE, van der Flier WM, Jokinen H, Lee A, Leroi I, Lojo-Seoane C, Milošević V, Molinuevo JL, Pereiro Rozas AX, Ritchie C, Salloway S, ... ... Scheltens P, et al. The influence of diversity on the measurement of functional impairment: An international validation of the Amsterdam IADL Questionnaire in eight countries. Alzheimer's & Dementia (Amsterdam, Netherlands). 12: e12021. PMID 32420446 DOI: 10.1002/dad2.12021  0.84
2020 Wolters EE, Ossenkoppele R, Verfaillie SCJ, Coomans EM, Timmers T, Visser D, Tuncel H, Golla SSV, Windhorst AD, Boellaard R, van der Flier WM, Teunissen CE, Scheltens P, van Berckel BNM. Correction to: Regional [F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging. PMID 32388611 DOI: 10.1007/s00259-020-04849-0  0.84
2020 Jutten RJ, Harrison JE, Brunner AJ, Vreeswijk R, van Deelen RAJ, de Jong FJ, Opmeer EM, Ritchie CW, Aleman A, Scheltens P, Sikkes SAM. The Cognitive-Functional Composite is sensitive to clinical progression in early dementia: Longitudinal findings from the Catch-Cog study cohort. Alzheimer's & Dementia (New York, N. Y.). 6: e12020. PMID 32313832 DOI: 10.1002/trc2.12020  0.6
2020 Reus LM, Stringer S, Posthuma D, Teunissen CE, Scheltens P, Pijnenburg YAL, Visser PJ, Tijms BM. Degree of genetic liability for Alzheimer's disease associated with specific proteomic profiles in cerebrospinal fluid. Neurobiology of Aging. PMID 32307133 DOI: 10.1016/j.neurobiolaging.2020.03.012  0.76
2020 Wolters EE, Ossenkoppele R, Verfaillie SCJ, Coomans EM, Timmers T, Visser D, Tuncel H, Golla SSV, Windhorst AD, Boellaard R, van der Flier WM, Teunissen CE, Scheltens P, van Berckel BNM. Regional [F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging. PMID 32291510 DOI: 10.1007/s00259-020-04758-2  0.84
2020 Lopes Alves I, Collij LE, Altomare D, Frisoni GB, Saint-Aubert L, Payoux P, Kivipelto M, Jessen F, Drzezga A, Leeuwis A, Wink AM, Visser PJ, van Berckel BNM, Scheltens P, Gray KR, et al. Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 32281303 DOI: 10.1002/alz.12069  1
2020 Pitkänen J, Koikkalainen J, Nieminen T, Marinkovic I, Curtze S, Sibolt G, Jokinen H, Rueckert D, Barkhof F, Schmidt R, Pantoni L, Scheltens P, Wahlund LO, Korvenoja A, Lötjönen J, et al. Evaluating severity of white matter lesions from computed tomography images with convolutional neural network. Neuroradiology. PMID 32281028 DOI: 10.1007/s00234-020-02410-2  1
2020 Kleineidam L, Chouraki V, Próchnicki T, van der Lee SJ, Madrid-Márquez L, Wagner-Thelen H, Karaca I, Weinhold L, Wolfsgruber S, Boland A, Martino Adami PV, Lewczuk P, Popp J, Brosseron F, Jansen IE, ... ... Scheltens P, et al. PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment. Acta Neuropathologica. PMID 32166339 DOI: 10.1007/s00401-020-02138-6  0.84
2020 Fieldhouse JLP, Doorduijn AS, de Leeuw FA, Verhaar BJH, Koene T, Wesselman LMP, Schueren MV, Visser M, Rest OV, Scheltens P, Kester MI, Flier WMV. A Suboptimal Diet is Associated with Poorer Cognition: The NUDAD Project. Nutrients. 12. PMID 32155876 DOI: 10.3390/nu12030703  0.72
2020 Trieu C, Gossink F, Stek ML, Scheltens P, Pijnenburg YAL, Dols A. Effectiveness of Pharmacological Interventions for Symptoms of Behavioral Variant Frontotemporal Dementia: A Systematic Review. Cognitive and Behavioral Neurology : Official Journal of the Society For Behavioral and Cognitive Neurology. 33: 1-15. PMID 32132398 DOI: 10.1097/WNN.0000000000000217  0.44
2020 Vignoli A, Paciotti S, Tenori L, Eusebi P, Biscetti L, Chiasserini D, Scheltens P, Turano P, Teunissen C, Luchinat C, Parnetti L. Fingerprinting Alzheimer's Disease by H Nuclear Magnetic Resonance Spectroscopy of Cerebrospinal Fluid. Journal of Proteome Research. PMID 32118444 DOI: 10.1021/acs.jproteome.9b00850  0.4
2020 Beker N, Sikkes SAM, Hulsman M, Tesi N, van der Lee SJ, Scheltens P, Holstege H. Longitudinal Maintenance of Cognitive Health in Centenarians in the 100-plus Study. Jama Network Open. 3: e200094. PMID 32101309 DOI: 10.1001/jamanetworkopen.2020.0094  0.6
2020 Verberk IMW, Hendriksen HMA, van Harten AC, Wesselman LMP, Verfaillie SCJ, van den Bosch KA, Slot RER, Prins ND, Scheltens P, Teunissen CE, Van der Flier WM. Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project. Neurobiology of Aging. PMID 32081465 DOI: 10.1016/j.neurobiolaging.2020.01.007  0.84
2020 de Leeuw FA, van der Flier WM, Tijms BM, Scheltens P, Mendes VM, Manadas B, Bierau J, van Wijk N, van den Heuvel EGHM, Mohajeri MH, Teunissen CE, Kester MI. Specific Nutritional Biomarker Profiles in Mild Cognitive Impairment and Subjective Cognitive Decline Are Associated With Clinical Progression: The NUDAD Project. Journal of the American Medical Directors Association. PMID 32001171 DOI: 10.1016/j.jamda.2019.12.009  0.84
2020 Westwood S, Baird AL, Anand SN, Nevado-Holgado AJ, Kormilitzin A, Shi L, Hye A, Ashton NJ, Morgan AR, Bos I, Vos SJB, Baker S, Buckley NJ, Ten Kate M, Scheltens P, et al. Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. Journal of Alzheimer's Disease : Jad. PMID 31985466 DOI: 10.3233/JAD-190434  1
2020 van der Lee SJ, Conway OJ, Jansen I, Carrasquillo MM, Kleineidam L, van den Akker E, Hernández I, van Eijk KR, Stringa N, Chen JA, Zettergren A, Andlauer TFM, Diez-Fairen M, Simon-Sanchez J, Lleó A, ... ... Scheltens P, et al. Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathologica. PMID 31955222 DOI: 10.1007/s00401-019-02107-8  0.84
2020 Rhodius-Meester HFM, van Maurik IS, Koikkalainen J, Tolonen A, Frederiksen KS, Hasselbalch SG, Soininen H, Herukka SK, Remes AM, Teunissen CE, Barkhof F, Pijnenburg YAL, Scheltens P, Lötjönen J, van der Flier WM. Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy. Plos One. 15: e0226784. PMID 31940390 DOI: 10.1371/journal.pone.0226784  1
2020 Leijenaar JF, Groeneveld GJ, Klaassen ES, Leeuwis AE, Scheltens P, Weinstein HC, van Gerven JMA, Barkhof F, van der Flier WM, Prins ND. Methylphenidate and galantamine in patients with vascular cognitive impairment-the proof-of-principle study STREAM-VCI. Alzheimer's Research & Therapy. 12: 10. PMID 31910895 DOI: 10.1186/s13195-019-0567-z  1
2020 Vermunt L, Muniz-Terrera G, Ter Meulen L, Veal C, Blennow K, Campbell A, Carrié I, Delrieu J, Fauria K, Huesa Rodríguez G, Ingala S, Jenkins N, Molinuevo JL, Ousset PJ, Porteous D, ... ... Scheltens P, et al. Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings. Alzheimer's Research & Therapy. 12: 8. PMID 31907067 DOI: 10.1186/s13195-019-0576-y  0.72
2019 Stamate D, Kim M, Proitsi P, Westwood S, Baird A, Nevado-Holgado A, Hye A, Bos I, Vos SJB, Vandenberghe R, Teunissen CE, Kate MT, Scheltens P, Gabel S, Meersmans K, et al. A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. Alzheimer's & Dementia (New York, N. Y.). 5: 933-938. PMID 31890857 DOI: 10.1016/j.trci.2019.11.001  0.72
2019 Dufresne J, Bowden P, Thavarajah T, Florentinus-Mefailoski A, Chen ZZ, Tucholska M, Norzin T, Ho MT, Phan M, Mohamed N, Ravandi A, Stanton E, Slutsky AS, Dos Santos CC, Romaschin A, ... ... Scheltens P, et al. The plasma peptides of breast versus ovarian cancer. Clinical Proteomics. 16: 43. PMID 31889940 DOI: 10.1186/s12014-019-9262-0  0.4
2019 Wolters EE, Ossenkoppele R, Golla SS, Verfaillie SC, Timmers T, Visser D, Tuncel H, Coomans EM, Windhorst AD, Scheltens P, van der Flier WM, Boellaard R, van Berckel BN. Hippocampal [F]flortaucipir BP corrected for possible spill-in of the choroid plexus retains strong clinico-pathological relationships. Neuroimage. Clinical. 25: 102113. PMID 31835238 DOI: 10.1016/j.nicl.2019.102113  0.84
2019 Reimand J, de Wilde A, Teunissen CE, Zwan M, Windhorst AD, Boellaard R, Barkhof F, van der Flier WM, Scheltens P, van Berckel BNM, Ossenkoppele R, Bouwman F. PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases. Alzheimer's Research & Therapy. 11: 100. PMID 31810489 DOI: 10.1186/s13195-019-0561-5  1
2019 Reimand J, Groot C, Teunissen CE, Windhorst AD, Boellaard R, Barkhof F, Nazarenko S, van der Flier WM, van Berckel BNM, Scheltens P, Ossenkoppele R, Bouwman F. Why Is Amyloid-β PET Requested After Performing Cerebrospinal Fluid Biomarkers? Journal of Alzheimer's Disease : Jad. PMID 31796674 DOI: 10.3233/JAD-190836  1
2019 Leijenaar JF, Groot C, Sudre CH, Bergeron D, Leeuwis AE, Cardoso MJ, Carrasco FP, Laforce R, Barkhof F, van der Flier WM, Scheltens P, Prins ND, Ossenkoppele R. Comorbid amyloid-β pathology affects clinical and imaging features in VCD. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 31786129 DOI: 10.1016/j.jalz.2019.08.190  1
2019 Jokinen H, Koikkalainen J, Laakso HM, Melkas S, Nieminen T, Brander A, Korvenoja A, Rueckert D, Barkhof F, Scheltens P, Schmidt R, Fazekas F, Madureira S, Verdelho A, Wallin A, et al. Global Burden of Small Vessel Disease-Related Brain Changes on MRI Predicts Cognitive and Functional Decline. Stroke. STROKEAHA119026170. PMID 31699021 DOI: 10.1161/STROKEAHA.119.026170  1
2019 Scheltens NME, Briels CT, Yaqub M, Barkhof F, Boellaard R, van der Flier WM, Schwarte LA, Teunissen CE, Attali A, Broersen LM, van Berckel BNM, Scheltens P. Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease. Alzheimer's & Dementia (New York, N. Y.). 5: 492-500. PMID 31650005 DOI: 10.1016/j.trci.2019.08.002  1
2019 Banning LCP, Janssen EPCJ, Hamel REG, de Vugt M, Köhler S, Wolfs CAG, Oosterveld SM, Melis RJF, Olde Rikkert MGM, Kessels RPC, Pijnenburg YAL, Koene T, van der Flier WM, Scheltens P, Visser PJ, et al. Determinants of Cross-Sectional and Longitudinal Health-Related Quality of Life in Memory Clinic Patients Without Dementia. Journal of Geriatric Psychiatry and Neurology. 891988719882104. PMID 31645191 DOI: 10.1177/0891988719882104  0.84
2019 van Steenoven I, van der Flier WM, Scheltens P, Teunissen CE, Lemstra AW. Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies. Alzheimer's Research & Therapy. 11: 83. PMID 31601267 DOI: 10.1186/s13195-019-0537-5  0.84
2019 Altomare D, de Wilde A, Ossenkoppele R, Pelkmans W, Bouwman F, Groot C, van Maurik I, Zwan M, Yaqub M, Barkhof F, van Berckel BN, Teunissen CE, Frisoni GB, Scheltens P, van der Flier WM. Applying the ATN scheme in a memory clinic population: The ABIDE project. Neurology. PMID 31597710 DOI: 10.1212/WNL.0000000000008361  1
2019 de Wilde A, Ossenkoppele R, Pelkmans W, Bouwman F, Groot C, van Maurik I, Zwan M, Yaqub M, Barkhof F, Lammertsma AA, Biessels GJ, Scheltens P, van Berckel BN, van der Flier WM. Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 31594684 DOI: 10.1016/j.jalz.2019.07.003  1
2019 van Maurik IS, Vos SJ, Bos I, Bouwman FH, Teunissen CE, Scheltens P, Barkhof F, Frolich L, Kornhuber J, Wiltfang J, Maier W, Peters O, Rüther E, Nobili F, Frisoni GB, et al. Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. The Lancet. Neurology. PMID 31526625 DOI: 10.1016/S1474-4422(19)30283-2  1
2019 de Wilde A, Reimand J, Teunissen CE, Zwan M, Windhorst AD, Boellaard R, van der Flier WM, Scheltens P, van Berckel BNM, Bouwman F, Ossenkoppele R. Discordant amyloid-β PET and CSF biomarkers and its clinical consequences. Alzheimer's Research & Therapy. 11: 78. PMID 31511058 DOI: 10.1186/s13195-019-0532-x  0.84
2019 Weaver NA, Doeven T, Barkhof F, Biesbroek JM, Groeneveld ON, Kuijf HJ, Prins ND, Scheltens P, Teunissen CE, van der Flier WM, Biessels GJ. Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions. Neurobiology of Aging. PMID 31500909 DOI: 10.1016/j.neurobiolaging.2019.08.001  1
2019 Shi L, Westwood S, Baird AL, Winchester L, Dobricic V, Kilpert F, Hong S, Franke A, Hye A, Ashton NJ, Morgan AR, Bos I, Vos SJB, Buckley NJ, Kate MT, ... Scheltens P, et al. Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 31495601 DOI: 10.1016/j.jalz.2019.06.4951  1
2019 Bertens D, Vos S, Kehoe P, Wolf H, Nobili F, Mendonça A, van Rossum I, Hort J, Molinuevo JL, Heneka M, Petersen R, Scheltens P, Visser PJ. Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey. Alzheimer's Research & Therapy. 11: 74. PMID 31439020 DOI: 10.1186/s13195-019-0525-9  0.52
2019 Legdeur N, Tijms BM, Konijnenberg E, den Braber A, Ten Kate M, Sudre CH, Tomassen J, Badissi M, Yaqub M, Barkhof F, van Berckel BN, Boomsma DI, Scheltens P, Holstege H, Maier AB, et al. Associations of brain pathology, cognitive and physical markers with age in cognitively normal individuals aged 60-102 years. The Journals of Gerontology. Series a, Biological Sciences and Medical Sciences. PMID 31411322 DOI: 10.1093/gerona/glz180  1
2019 van Maurik IS, van der Kall LM, de Wilde A, Bouwman FH, Scheltens P, van Berckel BNM, Berkhof J, van der Flier WM. Added value of amyloid PET in individualized risk predictions for MCI patients. Alzheimer's & Dementia (Amsterdam, Netherlands). 11: 529-537. PMID 31388557 DOI: 10.1016/j.dadm.2019.04.011  0.84
2019 Visser LNC, Kunneman M, Murugesu L, van Maurik I, Zwan M, Bouwman FH, Schuur J, Wind HA, Blaauw MSJ, Kragt JJ, Roks G, Boelaarts L, Schipper AC, Schooneboom N, Scheltens P, et al. Clinician-patient communication during the diagnostic workup: The ABIDE project. Alzheimer's & Dementia (Amsterdam, Netherlands). 11: 520-528. PMID 31388556 DOI: 10.1016/j.dadm.2019.06.001  0.84
2019 Verwey NA, Teunissen CE, Hoozemans JJM, Rozemuller AJM, Scheltens P, Pijnenburg YAL. Cerebrospinal Fluid Amyloid-β Subtypes in Confirmed Frontotemporal Lobar Degeneration Cases: A Pilot Study. Journal of Alzheimer's Disease : Jad. PMID 31356209 DOI: 10.3233/JAD-190344  0.72
2019 den Haan J, Csinscik L, Parker T, Paterson RW, Slattery CF, Foulkes A, Bouwman FH, Verbraak FD, Scheltens P, Peto T, Lengyel I, Schott JM, Crutch SJ, Shakespeare TJ, Yong KXX. Retinal thickness as potential biomarker in posterior cortical atrophy and typical Alzheimer's disease. Alzheimer's Research & Therapy. 11: 62. PMID 31319885 DOI: 10.1186/s13195-019-0516-x  0.72
2019 van Maurik IS, Visser LN, Pel-Littel RE, van Buchem MM, Zwan MD, Kunneman M, Pelkmans W, Bouwman FH, Minkman M, Schoonenboom N, Scheltens P, Smets EM, van der Flier WM. Development and Usability of ADappt: Web-Based Tool to Support Clinicians, Patients, and Caregivers in the Diagnosis of Mild Cognitive Impairment and Alzheimer Disease. Jmir Formative Research. 3: e13417. PMID 31287061 DOI: 10.2196/13417  0.84
2019 Timmers T, Ossenkoppele R, Wolters EE, Verfaillie SCJ, Visser D, Golla SSV, Barkhof F, Scheltens P, Boellaard R, van der Flier WM, van Berckel BNM. Associations between quantitative [F]flortaucipir tau PET and atrophy across the Alzheimer's disease spectrum. Alzheimer's Research & Therapy. 11: 60. PMID 31272512 DOI: 10.1186/s13195-019-0510-3  1
2019 Altomare D, Ferrari C, Caroli A, Galluzzi S, Prestia A, van der Flier WM, Ossenkoppele R, Van Berckel B, Barkhof F, Teunissen CE, Wall A, Carter SF, Schöll M, Choo ILH, Grimmer T, ... ... Scheltens P, et al. Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset. Journal of Neurology. PMID 31267207 DOI: 10.1007/s00415-019-09441-7  1
2019 van Loenhoud AC, van der Flier WM, Wink AM, Dicks E, Groot C, Twisk J, Barkhof F, Scheltens P, Ossenkoppele R. Cognitive reserve and clinical progression in Alzheimer disease: A paradoxical relationship. Neurology. PMID 31266904 DOI: 10.1212/WNL.0000000000007821  1
2019 Haan JD, van de Kreeke JA, Konijnenberg E, Kate MT, Braber AD, Barkhof F, van Berckel BN, Teunissen CE, Scheltens P, Visser PJ, Verbraak FD, Bouwman FH. Retinal thickness as a potential biomarker in patients with amyloid-proven early- and late-onset Alzheimer's disease. Alzheimer's & Dementia (Amsterdam, Netherlands). 11: 463-471. PMID 31249859 DOI: 10.1016/j.dadm.2019.05.002  1
2019 Babapour Mofrad R, Visser LNC, Fruijtier AD, Scheltens P, Smets EEMA, van der Flier WM, Teunissen CE. Cerebrospinal fluid collection: An informative animation video for patients and caregivers. Alzheimer's & Dementia (Amsterdam, Netherlands). 11: 435-438. PMID 31211216 DOI: 10.1016/j.dadm.2019.04.005  0.84
2019 Haan JD, van de Kreeke JA, van Berckel BN, Barkhof F, Teunissen CE, Scheltens P, Verbraak FD, Bouwman FH. Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease? Alzheimer's & Dementia (Amsterdam, Netherlands). 11: 383-391. PMID 31193094 DOI: 10.1016/j.dadm.2019.03.006  1
2019 Legdeur N, Visser PJ, Woodworth DC, Muller M, Fletcher E, Maillard P, Scheltens P, DeCarli C, Kawas CH, Corrada MM. White Matter Hyperintensities and Hippocampal Atrophy in Relation to Cognition: The 90+ Study. Journal of the American Geriatrics Society. PMID 31169919 DOI: 10.1111/jgs.15990  0.68
2019 Vermunt L, Sikkes SAM, van den Hout A, Handels R, Bos I, van der Flier WM, Kern S, Ousset PJ, Maruff P, Skoog I, Verhey FRJ, Freund-Levi Y, Tsolaki M, Wallin ÅK, Olde Rikkert M, ... ... Scheltens P, et al. Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 31164314 DOI: 10.1016/j.jalz.2019.04.001  0.84
2019 Pelkmans W, Dicks E, Barkhof F, Vrenken H, Scheltens P, van der Flier WM, Tijms BM. Gray matter T1-w/T2-w ratios are higher in Alzheimer's disease. Human Brain Mapping. PMID 31157938 DOI: 10.1002/hbm.24638  1
2019 van der Lee SJ, Conway OJ, Jansen I, Carrasquillo MM, Kleineidam L, van den Akker E, Hernández I, van Eijk KR, Stringa N, Chen JA, Zettergren A, Andlauer TFM, Diez-Fairen M, Simon-Sanchez J, Lleó A, ... ... Scheltens P, et al. A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathologica. PMID 31131421 DOI: 10.1007/s00401-019-02026-8  0.84
2019 Doorduijn AS, Visser M, van de Rest O, Kester MI, de Leeuw FA, Boesveldt S, Fieldhouse JLP, van den Heuvel EGHM, Teunissen CE, Scheltens P, van der Flier WM, de van der Schueren MAE. Associations of AD Biomarkers and Cognitive Performance with Nutritional Status: The NUDAD Project. Nutrients. 11. PMID 31126170 DOI: 10.3390/nu11051161  0.84
2019 Eikelboom WS, Singleton E, van den Berg E, Coesmans M, Mattace Raso F, van Bruchem RL, Goudzwaard JA, de Jong FJ, Koopmanschap M, den Heijer T, Driesen JJM, Vroegindeweij LJHM, Thomeer EC, Hoogers SE, Dijkstra AA, ... ... Scheltens P, et al. Early recognition and treatment of neuropsychiatric symptoms to improve quality of life in early Alzheimer's disease: protocol of the BEAT-IT study. Alzheimer's Research & Therapy. 11: 48. PMID 31122267 DOI: 10.1186/s13195-019-0503-2  0.6
2019 Liebsch F, Kulic L, Teunissen C, Shobo A, Ulku I, Engelschalt V, Hancock MA, van der Flier WM, Kunach P, Rosa-Neto P, Scheltens P, Poirier J, Saftig P, Bateman RJ, Breitner J, et al. Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression. Nature Communications. 10: 2240. PMID 31110178 DOI: 10.1038/s41467-019-10152-w  0.84
2019 Jutten RJ, Harrison JE, Lee Meeuw Kjoe PR, Ingala S, Vreeswijk R, van Deelen RAJ, de Jong FJ, Opmeer EM, Aleman A, Ritchie CW, Scheltens P, Sikkes SAM. Assessing cognition and daily function in early dementia using the cognitive-functional composite: findings from the Catch-Cog study cohort. Alzheimer's Research & Therapy. 11: 45. PMID 31092277 DOI: 10.1186/s13195-019-0500-5  0.6
2019 Wesselman LMP, Doorduijn AS, de Leeuw FA, Verfaillie SCJ, van Leeuwenstijn-Koopman M, Slot RER, Kester MI, Prins ND, van de Rest O, de van der Schueren MAE, Scheltens P, Sikkes SAM, van der Flier WM. Dietary Patterns Are Related to Clinical Characteristics in Memory Clinic Patients with Subjective Cognitive Decline: The SCIENCe Project. Nutrients. 11. PMID 31083522 DOI: 10.3390/nu11051057  0.84
2019 Kim M, Snowden S, Suvitaival T, Ali A, Merkler DJ, Ahmad T, Westwood S, Baird A, Proitsi P, Nevado-Holgado A, Hye A, Bos I, Vos S, Vandenberghe R, Teunissen C, ... ... Scheltens P, et al. Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 31078433 DOI: 10.1016/j.jalz.2019.03.004  1
2019 Verfaillie SCJ, Witteman J, Slot RER, Pruis I, Vermaat LEW, Prins ND, Schiller NO, van de Wiel M, Scheltens P, van Berckel BNM, van der Flier WM, Sikkes SAM. High amyloid burden is associated with fewer specific words during spontaneous speech in individuals with subjective cognitive decline. Neuropsychologia. PMID 31075283 DOI: 10.1016/j.neuropsychologia.2019.05.006  0.84
2019 Vermunt L, van Paasen AJL, Teunissen CE, Scheltens P, Visser PJ, Tijms BM. Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal. Neurology. PMID 31068481 DOI: 10.1212/WNL.0000000000007609  0.76
2019 Morgan AR, Touchard S, Leckey C, O'Hagan C, Nevado-Holgado AJ, Barkhof F, Bertram L, Blin O, Bos I, Dobricic V, Engelborghs S, Frisoni G, Frölich L, Gabel S, ... ... Scheltens P, et al. Inflammatory biomarkers in Alzheimer's disease plasma. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 31047856 DOI: 10.1016/j.jalz.2019.03.007  1
2019 Fuermaier ABM, Piersma D, de Waard D, Davidse RJ, de Groot J, Doumen MJA, Bredewoud RA, Claesen R, Lemstra AW, Scheltens P, Vermeeren A, Ponds R, Verhey F, De Deyn PP, Brouwer WH, et al. Driving Difficulties Among Patients with Alzheimer's Disease and Other Neurodegenerative Disorders. Journal of Alzheimer's Disease : Jad. PMID 31045516 DOI: 10.3233/JAD-181095  0.64
2019 Slot RER, Kester MI, Van Harten AC, Jongbloed W, Bouwman FH, Teunissen CE, Scheltens P, van der Flier WM, Veerhuis R. ApoE and clusterin CSF levels influence associations between APOE genotype and changes in CSF tau, but not CSF Aβ42, levels in non-demented elderly. Neurobiology of Aging. 79: 101-109. PMID 31029938 DOI: 10.1016/j.neurobiolaging.2019.02.017  0.84
2019 Timmers T, Ossenkoppele R, Verfaillie SCJ, van der Weijden CWJ, Slot RER, Wesselman LMP, Windhorst AD, Wolters EE, Yaqub M, Prins ND, Lammertsma AA, Scheltens P, van der Flier WM, van Berckel BNM. Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCe project. Neurobiology of Aging. 79: 50-58. PMID 31026622 DOI: 10.1016/j.neurobiolaging.2019.02.020  0.84
2019 Leeuwis AE, Weaver NA, Biesbroek JM, Exalto LG, Kuijf HJ, Hooghiemstra AM, Prins ND, Scheltens P, Barkhof F, van der Flier WM, Biessels GJ. Impact of white matter hyperintensity location on depressive symptoms in memory-clinic patients: a lesion–symptom mapping study Journal of Psychiatry & Neuroscience : Jpn. 44: 1-10. PMID 31021068 DOI: 10.1503/jpn.180136  1
2019 van Maurik IS, Slot RER, Verfaillie SCJ, Zwan MD, Bouwman FH, Prins ND, Teunissen CE, Scheltens P, Barkhof F, Wattjes MP, Molinuevo JL, Rami L, Wolfsgruber S, Peters O, Jessen F, et al. Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project. Alzheimer's Research & Therapy. 11: 33. PMID 30987684 DOI: 10.1186/s13195-019-0487-y  1
2019 Lleó A, Alcolea D, Martínez-Lage P, Scheltens P, Parnetti L, Poirier J, Simonsen AH, Verbeek MM, Rosa-Neto P, Slot RER, Tainta M, Izaguirre A, Reijs BLR, Farotti L, Tsolaki M, et al. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 30967340 DOI: 10.1016/j.jalz.2019.01.015  0.72
2019 Dicks E, Vermunt L, van der Flier WM, Visser PJ, Barkhof F, Scheltens P, Tijms BM. Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease. Neuroimage. Clinical. 22: 101786. PMID 30921610 DOI: 10.1016/j.nicl.2019.101786  1
2019 Boomsma JMF, Exalto LG, Barkhof F, Berg EVD, Bresser J, Heinen R, Leeuwis AE, Prins ND, Scheltens P, Weinstein HC, van der Flier WM, Biessels GJ. How Do Different Forms of Vascular Brain Injury Relate to Cognition in a Memory Clinic Population: The TRACE-VCI Study. Journal of Alzheimer's Disease : Jad. PMID 30909212 DOI: 10.3233/JAD-180696  1
2019 Bos I, Vos S, Verhey F, Scheltens P, Teunissen C, Engelborghs S, Sleegers K, Frisoni G, Blin O, Richardson JC, Bordet R, Tsolaki M, Popp J, Peyratout G, Martinez-Lage P, et al. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 30853464 DOI: 10.1016/j.jalz.2019.01.004  1
2019 Koikkalainen JR, Rhodius-Meester HFM, Frederiksen KS, Bruun M, Hasselbalch SG, Baroni M, Mecocci P, Vanninen R, Remes A, Soininen H, van Gils M, van der Flier WM, Scheltens P, Barkhof F, Erkinjuntti T, et al. Automatically computed rating scales from MRI for patients with cognitive disorders. European Radiology. PMID 30796570 DOI: 10.1007/s00330-019-06067-1  1
2019 Konijnenberg E, den Braber A, Ten Kate M, Tomassen J, Mulder SD, Yaqub M, Teunissen CE, Lammertsma AA, van Berckel BNM, Scheltens P, Boomsma DI, Visser PJ. Association of amyloid pathology with memory performance and cognitive complaints in cognitively normal older adults: a monozygotic twin study. Neurobiology of Aging. 77: 58-65. PMID 30784813 DOI: 10.1016/j.neurobiolaging.2019.01.006  0.72
2019 Groeneveld ON, Moneti C, Heinen R, de Bresser J, Kuijf HJ, Exalto LG, Boomsma JMF, Kappelle LJ, Barkhof F, Prins ND, Scheltens P, van der Flier WM, Biessels GJ. The Clinical Phenotype of Vascular Cognitive Impairment in Patients with Type 2 Diabetes Mellitus. Journal of Alzheimer's Disease : Jad. PMID 30775988 DOI: 10.3233/JAD-180914  1
2019 Verfaillie SCJ, Timmers T, Slot RER, van der Weijden CWJ, Wesselman LMP, Prins ND, Sikkes SAM, Yaqub M, Dols A, Lammertsma AA, Scheltens P, Ossenkoppele R, van Berckel BNM, van der Flier WM. Amyloid-β Load Is Related to Worries, but Not to Severity of Cognitive Complaints in Individuals With Subjective Cognitive Decline: The SCIENCe Project. Frontiers in Aging Neuroscience. 11: 7. PMID 30760996 DOI: 10.3389/fnagi.2019.00007  0.84
2019 Babapour Mofrad R, Schoonenboom NSM, Tijms BM, Scheltens P, Visser PJ, van der Flier WM, Teunissen CE. Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease. Alzheimer's & Dementia (Amsterdam, Netherlands). 11: 1-9. PMID 30569013 DOI: 10.1016/j.dadm.2018.10.004  0.84
2018 Rhodius-Meester HFM, Liedes H, Koikkalainen J, Wolfsgruber S, Coll-Padros N, Kornhuber J, Peters O, Jessen F, Kleineidam L, Molinuevo JL, Rami L, Teunissen CE, Barkhof F, Sikkes SAM, Wesselman LMP, ... ... Scheltens P, et al. Computer-assisted prediction of clinical progression in the earliest stages of AD. Alzheimer's & Dementia (Amsterdam, Netherlands). 10: 726-736. PMID 30619929 DOI: 10.1016/j.dadm.2018.09.001  1
2018 Westwood S, Baird AL, Hye A, Ashton NJ, Nevado-Holgado AJ, Anand SN, Liu B, Newby D, Bazenet C, Kiddle SJ, Ward M, Newton B, Desai K, Tan Hehir C, Zanette M, ... ... Scheltens P, et al. Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [F]-Flutemetamol PET Scan Result. Frontiers in Aging Neuroscience. 10: 409. PMID 30618716 DOI: 10.3389/fnagi.2018.00409  0.84
2018 Dufresne J, Bowden P, Thavarajah T, Florentinus-Mefailoski A, Chen ZZ, Tucholska M, Norzin T, Ho MT, Phan M, Mohamed N, Ravandi A, Stanton E, Slutsky AS, Dos Santos CC, Romaschin A, ... ... Scheltens P, et al. The plasma peptides of ovarian cancer. Clinical Proteomics. 15: 41. PMID 30598658 DOI: 10.1186/s12014-018-9215-z  0.72
2018 den Haan J, Morrema THJ, Verbraak FD, de Boer JF, Scheltens P, Rozemuller AJ, Bergen AAB, Bouwman FH, Hoozemans JJ. Amyloid-beta and phosphorylated tau in post-mortem Alzheimer's disease retinas. Acta Neuropathologica Communications. 6: 147. PMID 30593285 DOI: 10.1186/s40478-018-0650-x  0.72
2018 Beker N, Sikkes SAM, Hulsman M, Schmand B, Scheltens P, Holstege H. Neuropsychological Test Performance of Cognitively Healthy Centenarians: Normative Data From the Dutch 100-Plus Study. Journal of the American Geriatrics Society. PMID 30592018 DOI: 10.1111/jgs.15729  0.6
2018 Golla SS, Wolters EE, Timmers T, Ossenkoppele R, van der Weijden CW, Scheltens P, Schwarte L, Mintun MA, Devous MD, Schuit RC, Windhorst AD, Lammertsma AA, Yaqub M, van Berckel BN, Boellaard R. Parametric methods for [F]flortaucipir PET. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 271678X18820765. PMID 30569813 DOI: 10.1177/0271678X18820765  0.64
2018 Jutten RJ, Dicks E, Vermaat L, Barkhof F, Scheltens P, Tijms BM, Sikkes SAM. Impairment in complex activities of daily living is related to neurodegeneration in Alzheimer's disease-specific regions. Neurobiology of Aging. 75: 109-116. PMID 30557769 DOI: 10.1016/j.neurobiolaging.2018.11.018  1
2018 Slot RER, Sikkes SAM, Berkhof J, Brodaty H, Buckley R, Cavedo E, Dardiotis E, Guillo-Benarous F, Hampel H, Kochan NA, Lista S, Luck T, Maruff P, Molinuevo JL, Kornhuber J, ... ... Scheltens P, et al. Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 30555032 DOI: 10.1016/j.jalz.2018.10.003  0.84
2018 Dufresne J, Bowden P, Thavarajah T, Florentinus-Mefailoski A, Chen ZZ, Tucholska M, Norzin T, Ho MT, Phan M, Mohamed N, Ravandi A, Stanton E, Slutsky AS, Dos Santos CC, Romaschin A, ... ... Scheltens P, et al. The plasma peptidome. Clinical Proteomics. 15: 39. PMID 30519149 DOI: 10.1186/s12014-018-9211-3  0.4
2018 Legdeur N, Badissi M, Carter SF, de Crom S, van de Kreeke A, Vreeswijk R, Trappenburg MC, Oudega ML, Koek HL, van Campen JP, Keijsers CJPW, Amadi C, Hinz R, Gordon MF, Novak G, ... ... Scheltens P, et al. Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study. Bmc Geriatrics. 18: 289. PMID 30477432 DOI: 10.1186/s12877-018-0984-z  1
2018 Chakraborty A, Kamermans A, van Het Hof B, Castricum K, Aanhane E, van Horssen J, Thijssen VL, Scheltens P, Teunissen CE, Fontijn RD, van der Flier WM, de Vries HE. Angiopoietin like-4 as a novel vascular mediator in capillary cerebral amyloid angiopathy. Brain : a Journal of Neurology. PMID 30462206 DOI: 10.1093/brain/awy274  0.84
2018 Ten Kate M, Ingala S, Schwarz AJ, Fox NC, Chételat G, van Berckel BNM, Ewers M, Foley C, Gispert JD, Hill D, Irizarry MC, Lammertsma AA, Molinuevo JL, Ritchie C, Scheltens P, et al. Secondary prevention of Alzheimer's dementia: neuroimaging contributions. Alzheimer's Research & Therapy. 10: 112. PMID 30376881 DOI: 10.1186/s13195-018-0438-z  1
2018 Vogel JW, Mattsson N, Iturria-Medina Y, Strandberg OT, Schöll M, Dansereau C, Villeneuve S, van der Flier WM, Scheltens P, Bellec P, Evans AC, Hansson O, Ossenkoppele R. Data-driven approaches for tau-PET imaging biomarkers in Alzheimer's disease. Human Brain Mapping. PMID 30368979 DOI: 10.1002/hbm.24401  0.84
2018 Gossink FT, Vijverberg E, Krudop W, Scheltens P, Stek ML, Pijnenburg YAL, Dols A. Predicting progression in the late onset frontal lobe syndrome. International Psychogeriatrics. 1-6. PMID 30362933 DOI: 10.1017/S1041610218001242  0.44
2018 Holstege H, Beker N, Dijkstra T, Pieterse K, Wemmenhove E, Schouten K, Thiessens L, Horsten D, Rechtuijt S, Sikkes S, van Poppel FWA, Meijers-Heijboer H, Hulsman M, Scheltens P. The 100-plus Study of cognitively healthy centenarians: rationale, design and cohort description. European Journal of Epidemiology. PMID 30362018 DOI: 10.1007/s10654-018-0451-3  0.32
2018 Ten Kate M, Dicks E, Visser PJ, van der Flier WM, Teunissen CE, Barkhof F, Scheltens P, Tijms BM. Atrophy subtypes in prodromal Alzheimer's disease are associated with cognitive decline. Brain : a Journal of Neurology. PMID 30351346 DOI: 10.1093/brain/awy264  1
2018 Groot C, Sudre CH, Barkhof F, Teunissen CE, van Berckel BNM, Seo SW, Ourselin S, Scheltens P, Cardoso MJ, van der Flier WM, Ossenkoppele R. Clinical phenotype, atrophy, and small vessel disease in ε2 carriers with Alzheimer disease. Neurology. PMID 30341156 DOI: 10.1212/WNL.0000000000006503  1
2018 Frisoni GB, Barkhof F, Altomare D, Berkhof J, Boccardi M, Canzoneri E, Collij L, Drzezga A, Farrar G, Garibotto V, Gismondi R, Gispert JD, Jessen F, Kivipelto M, Alves IL, ... ... Scheltens P, et al. AMYPAD Diagnostic and Patient Management Study: Rationale and design. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 30339801 DOI: 10.1016/j.jalz.2018.09.003  1
2018 Bruun M, Rhodius-Meester HFM, Koikkalainen J, Baroni M, Gjerum L, Lemstra AW, Barkhof F, Remes AM, Urhemaa T, Tolonen A, Rueckert D, van Gils M, Frederiksen KS, Waldemar G, Scheltens P, et al. Evaluating combinations of diagnostic tests to discriminate different dementia types. Alzheimer's & Dementia (Amsterdam, Netherlands). 10: 509-518. PMID 30320203 DOI: 10.1016/j.dadm.2018.07.003  1
2018 Collij L, Konijnenberg E, Reimand J, Ten Kate M, Den Braber A, Lopes Alves I, Zwan M, Yaqub M, Van Assema D, Wink AM, Lammertsma A, Scheltens P, Visser PJ, Barkhof F, Van Berckel B. Assessing Amyloid Pathology in Cognitively Normal Subjects using [F]Flutemetamol PET: Comparing Visual Reads and Quantitative Methods. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 30315145 DOI: 10.2967/jnumed.118.211532  1
2018 Gardiner SL, Harder AVE, Campman YJM, Trompet S, Gussekloo J, van Belzen MJ, Boogaard MW, Roos RAC, Jansen IE, Pijnenburg YAL, Scheltens P, van der Flier WM, Aziz NA. Repeat length variations in ATXN1 and AR modify disease expression in Alzheimer's disease. Neurobiology of Aging. PMID 30314815 DOI: 10.1016/j.neurobiolaging.2018.09.007  0.84
2018 Scheltens P, Hallikainen M, Grimmer T, Duning T, Gouw AA, Teunissen CE, Wink AM, Maruff P, Harrison J, van Baal CM, Bruins S, Lues I, Prins ND. Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study. Alzheimer's Research & Therapy. 10: 107. PMID 30309389 DOI: 10.1186/s13195-018-0431-6  0.8
2018 Ten Kate M, Redolfi A, Peira E, Bos I, Vos SJ, Vandenberghe R, Gabel S, Schaeverbeke J, Scheltens P, Blin O, Richardson JC, Bordet R, Wallin A, Eckerstrom C, Molinuevo JL, et al. MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. Alzheimer's Research & Therapy. 10: 100. PMID 30261928 DOI: 10.1186/s13195-018-0428-1  1
2018 Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, Ashford E, Retout S, Hofmann C, Delmar P, Klein G, Andjelkovic M, Dubois B, Boada M, Blennow K, et al. Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. Alzheimer's Research & Therapy. 10: 99. PMID 30261916 DOI: 10.1186/s13195-018-0409-4  1
2018 Tesi N, van der Lee SJ, Hulsman M, Jansen IE, Stringa N, van Schoor N, Meijers-Heijboer H, Huisman M, Scheltens P, Reinders MJT, van der Flier WM, Holstege H. Centenarian controls increase variant effect sizes by an average twofold in an extreme case-extreme control analysis of Alzheimer's disease. European Journal of Human Genetics : Ejhg. PMID 30258121 DOI: 10.1038/s41431-018-0273-5  0.84
2018 Bergeron D, Gorno-Tempini ML, Rabinovici GD, Santos-Santos MA, Seeley W, Miller BL, Pijnenburg Y, Keulen MA, Groot C, van Berckel BNM, van der Flier WM, Scheltens P, Rohrer JD, Warren JD, Schott JM, et al. Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia. Annals of Neurology. PMID 30255971 DOI: 10.1002/ana.25333  0.84
2018 Tijms BM, Vermunt L, Zwan MD, van Harten AC, van der Flier WM, Teunissen CE, Scheltens P, Visser PJ. Pre-amyloid stage of Alzheimer's disease in cognitively normal individuals. Annals of Clinical and Translational Neurology. 5: 1037-1047. PMID 30250861 DOI: 10.1002/acn3.615  0.84
2018 Verberk IMW, Slot RE, Verfaillie SCJ, Heijst H, Prins ND, van Berckel BNM, Scheltens P, Teunissen CE, Van der Flier WM. Plasma amyloid as pre-screener for the earliest Alzheimer's pathological changes. Annals of Neurology. PMID 30196548 DOI: 10.1002/ana.25334  0.84
2018 van der Zande JJ, Steenwijk MD, Ten Kate M, Wattjes MP, Scheltens P, Lemstra AW. Gray matter atrophy in dementia with Lewy bodies with and without concomitant Alzheimer's disease pathology. Neurobiology of Aging. 71: 171-178. PMID 30149288 DOI: 10.1016/j.neurobiolaging.2018.07.005  0.72
2018 Wolters EE, Golla SSV, Timmers T, Ossenkoppele R, van der Weijden CWJ, Scheltens P, Schwarte L, Schuit RC, Windhorst AD, Barkhof F, Yaqub M, Lammertsma AA, Boellaard R, van Berckel BNM. A novel partial volume correction method for accurate quantification of [F] flortaucipir in the hippocampus. Ejnmmi Research. 8: 79. PMID 30112620 DOI: 10.1186/s13550-018-0432-2  1
2018 Scheltens NME, Tijms BM, Heymans MW, Rabinovici GD, Cohn-Sheehy BI, Miller BL, Kramer JH, Wolfsgruber S, Wagner M, Kornhuber J, Peters O, Scheltens P, van der Flier WM. Prominent Non-Memory Deficits in Alzheimer's Disease Are Associated with Faster Disease Progression. Journal of Alzheimer's Disease : Jad. PMID 30103316 DOI: 10.3233/JAD-171088  0.84
2018 Slot RER, Verfaillie SCJ, Overbeek JM, Timmers T, Wesselman LMP, Teunissen CE, Dols A, Bouwman FH, Prins ND, Barkhof F, Lammertsma AA, Van Berckel BNM, Scheltens P, Sikkes SAM, Van der Flier WM. Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results. Alzheimer's Research & Therapy. 10: 76. PMID 30081935 DOI: 10.1186/s13195-018-0390-y  1
2018 Konijnenberg E, Carter SF, Ten Kate M, den Braber A, Tomassen J, Amadi C, Wesselman L, Nguyen HT, van de Kreeke JA, Yaqub M, Demuru M, Mulder SD, Hillebrand A, Bouwman FH, Teunissen CE, ... ... Scheltens P, et al. The EMIF-AD PreclinAD study: study design and baseline cohort overview. Alzheimer's Research & Therapy. 10: 75. PMID 30075734 DOI: 10.1186/s13195-018-0406-7  1
2018 Gossink F, Pijnenburg Y, Scheltens P, Pera A, Kleverwal R, Korten N, Stek M, Dröes RM, Dols A. An intervention programme for caregivers of dementia patients with frontal behavioural changes: an explorative study with controlled effect on sense of competence. Psychogeriatrics : the Official Journal of the Japanese Psychogeriatric Society. PMID 30066463 DOI: 10.1111/psyg.12351  0.48
2018 de Wilde A, van Buchem MM, Otten RHJ, Bouwman F, Stephens A, Barkhof F, Scheltens P, van der Flier WM. Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review. Alzheimer's Research & Therapy. 10: 72. PMID 30055660 DOI: 10.1186/s13195-018-0398-3  1
2018 Rhodius-Meester HFM, Tijms BM, Lemstra AW, Prins ND, Pijnenburg YAL, Bouwman F, Scheltens P, van der Flier WM. Survival in memory clinic cohort is short, even in young-onset dementia. Journal of Neurology, Neurosurgery, and Psychiatry. PMID 30045942 DOI: 10.1136/jnnp-2018-318820  0.84
2018 Groot C, Tolboom N, Ikonomovic MD, Lammertsma AA, Boon BDC, Barkhof F, Scheltens P, Klunk WE, Rozemuller AJM, Ossenkoppele R, van Berckel BNM. Quantitative PET and Histology of Brain Biopsy Reveal Lack of Selective Pittsburgh Compound-B Binding to Intracerebral Amyloidoma. Journal of Alzheimer's Disease : Jad. PMID 30040724 DOI: 10.3233/JAD-180316  1
2018 Ganz AB, Beker N, Hulsman M, Sikkes S, Netherlands Brain Bank, Scheltens P, Smit AB, Rozemuller AJM, Hoozemans JJM, Holstege H. Neuropathology and cognitive performance in self-reported cognitively healthy centenarians. Acta Neuropathologica Communications. 6: 64. PMID 30037350 DOI: 10.1186/s40478-018-0558-5  0.32
2018 van der Zande JJ, Gouw AA, van Steenoven I, Scheltens P, Stam CJ, Lemstra AW. EEG Characteristics of Dementia With Lewy Bodies, Alzheimer's Disease and Mixed Pathology. Frontiers in Aging Neuroscience. 10: 190. PMID 30018548 DOI: 10.3389/fnagi.2018.00190  0.8
2018 Linszen MMJ, Lemstra AW, Dauwan M, Brouwer RM, Scheltens P, Sommer IEC. Understanding hallucinations in probable Alzheimer's disease: Very low prevalence rates in a tertiary memory clinic. Alzheimer's & Dementia (Amsterdam, Netherlands). 10: 358-362. PMID 30014034 DOI: 10.1016/j.dadm.2018.03.005  0.64
2018 Scheltens NME, van der Weijden K, Adriaanse SM, van Assema D, Oomen PP, Krudop WA, Lammertsma AA, Barkhof F, Koene T, Teunissen CE, Scheltens P, van der Flier WM, Pijnenburg YAL, Yaqub M, Ossenkoppele R, et al. Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease. Neuroimage. Clinical. 19: 625-632. PMID 29984170 DOI: 10.1016/j.nicl.2018.05.024  1
2018 Bos I, Vos S, Vandenberghe R, Scheltens P, Engelborghs S, Frisoni G, Molinuevo JL, Wallin A, Lleó A, Popp J, Martinez-Lage P, Baird A, Dobson R, Legido-Quigley C, Sleegers K, et al. The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. Alzheimer's Research & Therapy. 10: 64. PMID 29980228 DOI: 10.1186/s13195-018-0396-5  1
2018 Chakraborty A, Chatterjee M, Twaalfhoven H, Del Campo Milan M, Teunissen CE, Scheltens P, Fontijn RD, van Der Flier WM, de Vries HE. Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia. Alzheimer's Research & Therapy. 10: 58. PMID 29933741 DOI: 10.1186/s13195-018-0385-8  0.84
2018 Bos I, Verhey FR, Ramakers IHGB, Jacobs HIL, Soininen H, Freund-Levi Y, Hampel H, Tsolaki M, Wallin ÅK, van Buchem MA, Oleksik A, Verbeek MM, Rikkert MO, van der Flier WM, Scheltens P, et al. Correction to: Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline. Alzheimer's Research & Therapy. 10: 56. PMID 29925412 DOI: 10.1186/s13195-018-0391-x  0.84
2018 Tolonen A, Rhodius-Meester HFM, Bruun M, Koikkalainen J, Barkhof F, Lemstra AW, Koene T, Scheltens P, Teunissen CE, Tong T, Guerrero R, Schuh A, Ledig C, Baroni M, Rueckert D, et al. Data-Driven Differential Diagnosis of Dementia Using Multiclass Disease State Index Classifier. Frontiers in Aging Neuroscience. 10: 111. PMID 29922145 DOI: 10.3389/fnagi.2018.00111  1
2018 Golla SS, Verfaillie SC, Boellaard R, Adriaanse SM, Zwan MD, Schuit RC, Timmers T, Groot C, Schober P, Scheltens P, van der Flier WM, Windhorst AD, van Berckel BN, Lammertsma AA. Quantification of [F]florbetapir: A test-retest tracer kinetic modelling study. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 271678X18783628. PMID 29897009 DOI: 10.1177/0271678X18783628  0.84
2018 de Wilde A, van der Flier WM, Pelkmans W, Bouwman F, Verwer J, Groot C, van Buchem MM, Zwan M, Ossenkoppele R, Yaqub M, Kunneman M, Smets EMA, Barkhof F, Lammertsma AA, Stephens A, ... ... Scheltens P, et al. Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project. Jama Neurology. PMID 29889941 DOI: 10.1001/jamaneurol.2018.1346  1
2018 Boon BDC, Hoozemans JJM, Lopuhaä B, Eigenhuis KN, Scheltens P, Kamphorst W, Rozemuller AJM, Bouwman FH. Neuroinflammation is increased in the parietal cortex of atypical Alzheimer's disease. Journal of Neuroinflammation. 15: 170. PMID 29843759 DOI: 10.1186/s12974-018-1180-y  0.72
2018 Jutten RJ, Harrison J, Lee Meeuw Kjoe PR, Opmeer EM, Schoonenboom NSM, de Jong FJ, Ritchie CW, Scheltens P, Sikkes SAM. A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test-retest reliability and feasibility. Alzheimer's & Dementia (Amsterdam, Netherlands). 10: 153-160. PMID 29780863 DOI: 10.1016/j.dadm.2017.12.002  0.6
2018 Leeuwis AE, Prins ND, Hooghiemstra AM, Benedictus MR, Scheltens P, Barkhof F, van der Flier WM. Microbleeds are associated with depressive symptoms in Alzheimer's disease. Alzheimer's & Dementia (Amsterdam, Netherlands). 10: 112-120. PMID 29780860 DOI: 10.1016/j.dadm.2017.11.006  1
2018 Verfaillie SCJ, Pichet Binette A, Vachon-Presseau E, Tabrizi S, Savard M, Bellec P, Ossenkoppele R, Scheltens P, van der Flier WM, Breitner JCS, Villeneuve S. Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer's Disease. Biological Psychiatry. Cognitive Neuroscience and Neuroimaging. 3: 463-472. PMID 29735156 DOI: 10.1016/j.bpsc.2017.11.012  0.84
2018 Claus JJ, Coenen M, Staekenborg SS, Schuur J, Tielkes CEM, Koster P, Scheltens P. Cerebral White Matter Lesions have Low Impact on Cognitive Function in a Large Elderly Memory Clinic Population. Journal of Alzheimer's Disease : Jad. PMID 29710708 DOI: 10.3233/JAD-171111  0.76
2018 Scheltens P, Prins N, Lammertsma A, Yaqub M, Gouw A, Wink AM, Chu HM, van Berckel BNM, Alam J. An exploratory clinical study of p38 kinase inhibition in Alzheimer's disease. Annals of Clinical and Translational Neurology. 5: 464-473. PMID 29687023 DOI: 10.1002/acn3.549  0.72
2018 Dauwan M, Linszen MMJ, Lemstra AW, Scheltens P, Stam CJ, Sommer IE. EEG-based neurophysiological indicators of hallucinations in Alzheimer's disease: Comparison with dementia with Lewy bodies. Neurobiology of Aging. 67: 75-83. PMID 29653315 DOI: 10.1016/j.neurobiolaging.2018.03.013  0.64
2018 Bouts MJRJ, Möller C, Hafkemeijer A, van Swieten JC, Dopper E, van der Flier WM, Vrenken H, Wink AM, Pijnenburg YAL, Scheltens P, Barkhof F, Schouten TM, de Vos F, Feis RA, van der Grond J, et al. Single Subject Classification of Alzheimer's Disease and Behavioral Variant Frontotemporal Dementia Using Anatomical, Diffusion Tensor, and Resting-State Functional Magnetic Resonance Imaging. Journal of Alzheimer's Disease : Jad. PMID 29614652 DOI: 10.3233/JAD-170893  1
2018 Teunissen CE, Chiu MJ, Yang CC, Yang SY, Scheltens P, Zetterberg H, Blennow K. Plasma Amyloid-β (Aβ42) Correlates with Cerebrospinal Fluid Aβ42 in Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. PMID 29614646 DOI: 10.3233/JAD-170784  0.72
2018 Vermunt L, Veal CD, Meulen LT, Chrysostomou C, van der Flier W, Frisoni GB, Guessous I, Kivipelto M, Marizzoni M, Martinez-Lage P, Molinuevo JL, Porteus D, Ritchie K, Scheltens P, Ousset PJ, et al. European Prevention of Alzheimer's Dementia Registry: Recruitment and prescreening approach for a longitudinal cohort and prevention trials. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 29604264 DOI: 10.1016/j.jalz.2018.02.010  0.52
2018 Verfaillie SCJ, Slot RER, Dicks E, Prins ND, Overbeek JM, Teunissen CE, Scheltens P, Barkhof F, van der Flier WM, Tijms BM. A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline. Human Brain Mapping. PMID 29602212 DOI: 10.1002/hbm.24065  1
2018 Mattsson N, Groot C, Jansen WJ, Landau S, Villemagne V, Engelborghs S, Mintun M, Lleo A, Molinuevo JL, Jagust W, Frisoni GB, Ivanoiu A, Chételat G, Resende de Oliveira C, Rodrigue KM, ... ... Scheltens P, et al. Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 29601787 DOI: 10.1016/j.jalz.2018.02.009  0.84
2018 Ten Kate M, Visser PJ, Bakardjian H, Barkhof F, Sikkes SAM, van der Flier WM, Scheltens P, Hampel H, Habert MO, Dubois B, Tijms BM. Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults. Frontiers in Aging Neuroscience. 10: 67. PMID 29599717 DOI: 10.3389/fnagi.2018.00067  1
2018 van der Flier WM, Scheltens P. Amsterdam Dementia Cohort: Performing Research to Optimize Care. Journal of Alzheimer's Disease : Jad. 62: 1091-1111. PMID 29562540 DOI: 10.3233/JAD-170850  0.84
2018 Leijenaar JF, Groeneveld GJ, van der Flier WM, Scheltens P, Klaassen ES, Weinstein HC, Biessels GJ, Barkhof F, Prins ND. Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over Trial. Jmir Research Protocols. 7: e80. PMID 29559423 DOI: 10.2196/resprot.9192  1
2018 Willemse EAJ, De Vos A, Herries EM, Andreasson U, Engelborghs S, van der Flier WM, Scheltens P, Crimmins D, Ladenson JH, Vanmechelen E, Zetterberg H, Fagan AM, Blennow K, Bjerke M, Teunissen CE. Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study. Clinical Chemistry. PMID 29523639 DOI: 10.1373/clinchem.2017.283028  0.84
2018 Ten Kate M, Sudre CH, den Braber A, Konijnenberg E, Nivard MG, Cardoso MJ, Scheltens P, Ourselin S, Boomsma DI, Barkhof F, Visser PJ. White matter hyperintensities and vascular risk factors in monozygotic twins. Neurobiology of Aging. 66: 40-48. PMID 29505954 DOI: 10.1016/j.neurobiolaging.2018.02.002  1
2018 Gossink F, Schouws S, Krudop W, Scheltens P, Stek M, Pijnenburg Y, Dols A. Social Cognition Differentiates Behavioral Variant Frontotemporal Dementia From Other Neurodegenerative Diseases and Psychiatric Disorders. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. PMID 29501411 DOI: 10.1016/j.jagp.2017.12.008  0.48
2018 Rhodius-Meester HFM, Liedes H, Koene T, Lemstra AW, Teunissen CE, Barkhof F, Scheltens P, van Gils M, Lötjönen J, van der Flier WM. Disease-related determinants are associated with mortality in dementia due to Alzheimer's disease. Alzheimer's Research & Therapy. 10: 23. PMID 29458426 DOI: 10.1186/s13195-018-0348-0  1
2018 van der Flier WM, Skoog I, Schneider JA, Pantoni L, Mok V, Chen CLH, Scheltens P. Vascular cognitive impairment. Nature Reviews. Disease Primers. 4: 18003. PMID 29446769 DOI: 10.1038/nrdp.2018.3  0.84
2018 Liu E, Wang D, Sperling R, Salloway S, Fox NC, Blennow K, Scheltens P, Schmidt ME, Streffer J, Novak G, Einstein S, Booth K, Ketter N, Brashear HR. Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab. Neurology. PMID 29429971 DOI: 10.1212/WNL.0000000000005060  0.68
2018 Duits FH, Brinkmalm G, Teunissen CE, Brinkmalm A, Scheltens P, Van der Flier WM, Zetterberg H, Blennow K. Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease. Alzheimer's Research & Therapy. 10: 5. PMID 29370833 DOI: 10.1186/s13195-017-0335-x  0.84
2018 van der Lee SJ, Teunissen CE, Pool R, Shipley MJ, Teumer A, Chouraki V, Melo van Lent D, Tynkkynen J, Fischer K, Hernesniemi J, Metspalu A, Singh-Manoux A, Verhoeven A, Willemsen G, de Leeuw FA, ... ... Scheltens P, et al. Circulating metabolites and general cognitive ability and dementia: Evidence from 11 cohort studies. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 29316447 DOI: 10.1016/j.jalz.2017.11.012  0.84
2018 den Haan J, Janssen SF, van de Kreeke JA, Scheltens P, Verbraak FD, Bouwman FH. Retinal thickness correlates with parietal cortical atrophy in early-onset Alzheimer's disease and controls. Alzheimer's & Dementia (Amsterdam, Netherlands). 10: 49-55. PMID 29201990 DOI: 10.1016/j.dadm.2017.10.005  0.72
2017 Bos I, Verhey FR, Ramakers IHGB, Jacobs HIL, Soininen H, Freund-Levi Y, Hampel H, Tsolaki M, Wallin ÅK, van Buchem MA, Oleksik A, Verbeek MM, Olde Rikkert M, van der Flier WM, Scheltens P, et al. Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline. Alzheimer's Research & Therapy. 9: 101. PMID 29284531 DOI: 10.1186/s13195-017-0328-9  0.84
2017 Groot C, van Loenhoud AC, Barkhof F, van Berckel BNM, Koene T, Teunissen CC, Scheltens P, van der Flier WM, Ossenkoppele R. Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease. Neurology. PMID 29237798 DOI: 10.1212/WNL.0000000000004802  1
2017 Leijenaar JF, van Maurik IS, Kuijer JPA, van der Flier WM, Scheltens P, Barkhof F, Prins ND. Lower cerebral blood flow in subjects with Alzheimer's dementia, mild cognitive impairment, and subjective cognitive decline using two-dimensional phase-contrast magnetic resonance imaging. Alzheimer's & Dementia (Amsterdam, Netherlands). 9: 76-83. PMID 29234724 DOI: 10.1016/j.dadm.2017.10.001  1
2017 Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, Ashford E, Retout S, Hofmann C, Delmar P, Klein G, Andjelkovic M, Dubois B, Boada M, Blennow K, et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. Alzheimer's Research & Therapy. 9: 95. PMID 29221491 DOI: 10.1186/s13195-017-0318-y  1
2017 Tijms BM, Willemse EAJ, Zwan MD, Mulder SD, Visser PJ, van Berckel BNM, van der Flier WM, Scheltens P, Teunissen CE. Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid-β 1-42 Analysis Results. Clinical Chemistry. PMID 29208658 DOI: 10.1373/clinchem.2017.281055  0.84
2017 Piersma D, Fuermaier ABM, De Waard D, Davidse RJ, De Groot J, Doumen MJA, Bredewoud RA, Claesen R, Lemstra AW, Scheltens P, Vermeeren A, Ponds R, Verhey F, De Deyn PP, Brouwer WH, et al. Assessing Fitness to Drive in Patients With Different Types of Dementia. Alzheimer Disease and Associated Disorders. PMID 29189301 DOI: 10.1097/WAD.0000000000000221  0.64
2017 Jansen WJ, Ossenkoppele R, Tijms BM, Fagan AM, Hansson O, Klunk WE, van der Flier WM, Villemagne VL, Frisoni GB, Fleisher AS, Lleó A, Mintun MA, Wallin A, Engelborghs S, Na DL, ... ... Scheltens P, et al. Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia. Jama Psychiatry. PMID 29188296 DOI: 10.1001/jamapsychiatry.2017.3391  0.84
2017 Bertens D, Tijms BM, Vermunt L, Prins ND, Scheltens P, Visser PJ. The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design. Alzheimer's & Dementia (New York, N. Y.). 3: 513-523. PMID 29124109 DOI: 10.1016/j.trci.2017.08.005  0.76
2017 Dicks E, Tijms BM, Ten Kate M, Gouw AA, Benedictus MR, Teunissen CE, Barkhof F, Scheltens P, van der Flier WM. Gray matter network measures are associated with cognitive decline in mild cognitive impairment. Neurobiology of Aging. 61: 198-206. PMID 29111486 DOI: 10.1016/j.neurobiolaging.2017.09.029  1
2017 Vijverberg EGB, Gossink F, Krudop W, Sikkes S, Kerssens C, Prins N, Stek M, Scheltens P, Pijnenburg Y, Dols A. The Diagnostic Challenge of the Late-Onset Frontal Lobe Syndrome: Clinical Predictors for Primary Psychiatric Disorders Versus Behavioral Variant Frontotemporal Dementia. The Journal of Clinical Psychiatry. PMID 29099546 DOI: 10.4088/JCP.16m11078  0.48
2017 Jutten RJ, Harrison J, de Jong FJ, Aleman A, Ritchie CW, Scheltens P, Sikkes SAM. A composite measure of cognitive and functional progression in Alzheimer's disease: Design of the Capturing Changes in Cognition study. Alzheimer's & Dementia (New York, N. Y.). 3: 130-138. PMID 29067324 DOI: 10.1016/j.trci.2017.01.004  0.6
2017 Sartor J, Bettecken K, Bernhard FP, Hofmann M, Gladow T, Lindig T, Ciliz M, Ten Kate M, Geritz J, Heinzel S, Benedictus M, Scheltens P, Hobert MA, Maetzler W. Corrigendum: White Matter Changes-Related Gait and Executive Function Deficits: Associations with Age and Parkinson's Disease. Frontiers in Aging Neuroscience. 9: 342. PMID 29056907 DOI: 10.3389/fnagi.2017.00342  0.52
2017 van Maurik IS, Zwan MD, Tijms BM, Bouwman FH, Teunissen CE, Scheltens P, Wattjes MP, Barkhof F, Berkhof J, van der Flier WM. Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project. Jama Neurology. PMID 29049480 DOI: 10.1001/jamaneurol.2017.2712  1
2017 Skillbäck T, Mattsson N, Hansson K, Mirgorodskaya E, Dahlén R, van der Flier W, Scheltens P, Duits F, Hansson O, Teunissen C, Blennow K, Zetterberg H, Gobom J. A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer's disease. Scientific Reports. 7: 13333. PMID 29042634 DOI: 10.1038/s41598-017-13831-0  0.4
2017 Tijms BM, Ten Kate M, Gouw AA, Borta A, Verfaillie S, Teunissen CE, Scheltens P, Barkhof F, van der Flier WM. Gray matter networks and clinical progression in subjects with predementia Alzheimer's disease. Neurobiology of Aging. 61: 75-81. PMID 29040871 DOI: 10.1016/j.neurobiolaging.2017.09.011  1
2017 Reijs BLR, Vos SJB, Soininen H, Lötjonen J, Koikkalainen J, Pikkarainen M, Hall A, Vanninen R, Liu Y, Herukka SK, Freund-Levi Y, Frisoni GB, Frölich L, Nobili F, Rikkert MO, ... ... Scheltens P, et al. Association Between Later Life Lifestyle Factors and Alzheimer's Disease Biomarkers in Non-Demented Individuals: A Longitudinal Descriptive Cohort Study. Journal of Alzheimer's Disease : Jad. PMID 29036813 DOI: 10.3233/JAD-170039  0.64
2017 Verfaillie SCJ, Slot RE, Tijms BM, Bouwman F, Benedictus MR, Overbeek JM, Koene T, Vrenken H, Scheltens P, Barkhof F, van der Flier WM. Thinner cortex in patients with subjective cognitive decline is associated with steeper decline of memory. Neurobiology of Aging. PMID 29029762 DOI: 10.1016/j.neurobiolaging.2017.09.009  1
2017 Krudop WA, Dols A, Kerssens CJ, Eikelenboom P, Prins ND, Möller C, Schouws S, Rhebergen D, van Exel E, van der Flier WM, Sikkes S, Scheltens P, Stek ML, Pijnenburg YAL. The Pitfall of Behavioral Variant Frontotemporal Dementia Mimics Despite Multidisciplinary Application of the FTDC Criteria. Journal of Alzheimer's Disease : Jad. 60: 959-975. PMID 28984605 DOI: 10.3233/JAD-170608  0.84
2017 de Leeuw FA, Peeters CFW, Kester MI, Harms AC, Struys EA, Hankemeier T, van Vlijmen HWT, van der Lee SJ, van Duijn CM, Scheltens P, Demirkan A, van de Wiel MA, van der Flier WM, Teunissen CE. Blood-based metabolic signatures in Alzheimer's disease. Alzheimer's & Dementia (Amsterdam, Netherlands). 8: 196-207. PMID 28951883 DOI: 10.1016/j.dadm.2017.07.006  0.84
2017 Ten Kate M, Barkhof F, Visser PJ, Teunissen CE, Scheltens P, van der Flier WM, Tijms BM. Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment. Alzheimer's Research & Therapy. 9: 73. PMID 28899429 DOI: 10.1186/s13195-017-0299-x  1
2017 Miller AM, Balasa M, Blennow K, Gardiner M, Rutkowska A, Scheltens P, Teunissen CE, Visser PJ, Winblad B, Waldemar G, Lawlor B. Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe. Journal of Alzheimer's Disease : Jad. PMID 28826189 DOI: 10.3233/JAD-170502  0.72
2017 Vijverberg EGB, Schouws S, Meesters PD, Verwijk E, Comijs H, Koene T, Schreuder C, Beekman A, Scheltens P, Stek M, Pijnenburg Y, Dols A. Cognitive Deficits in Patients With Neuropsychiatric Symptoms: A Comparative Study Between Behavioral Variant Frontotemporal Dementia and Primary Psychiatric Disorders. The Journal of Clinical Psychiatry. PMID 28749089 DOI: 10.4088/JCP.16m11019  0.72
2017 Frisoni GB, Boccardi M, Barkhof F, Blennow K, Cappa S, Chiotis K, Démonet JF, Garibotto V, Giannakopoulos P, Gietl A, Hansson O, Herholz K, Jack CR, Nobili F, Nordberg A, ... ... Scheltens P, et al. Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. The Lancet. Neurology. 16: 661-676. PMID 28721928 DOI: 10.1016/S1474-4422(17)30159-X  1
2017 Sartor J, Bettecken K, Bernhard FP, Hofmann M, Gladow T, Lindig T, Ciliz M, Ten Kate M, Geritz J, Heinzel S, Benedictus M, Scheltens P, Hobert MA, Maetzler W. White Matter Changes-Related Gait and Executive Function Deficits: Associations with Age and Parkinson's Disease. Frontiers in Aging Neuroscience. 9: 213. PMID 28713264 DOI: 10.3389/fnagi.2017.00213  0.52
2017 Schindler SE, Sutphen CL, Teunissen C, McCue LM, Morris JC, Holtzman DM, Mulder SD, Scheltens P, Xiong C, Fagan AM. Upward drift in cerebrospinal fluid amyloid-β 42 assay values for more than 10 years. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 28710906 DOI: 10.1016/j.jalz.2017.06.2264  0.4
2017 van Wijk N, Slot RER, Duits FH, Strik M, Biesheuvel E, Sijben JWC, Blankenstein MA, Bierau J, van der Flier WM, Scheltens P, Teunissen CE. Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer's disease dementia. Alzheimer's & Dementia (Amsterdam, Netherlands). 8: 139-146. PMID 28653034 DOI: 10.1016/j.dadm.2017.04.005  0.84
2017 Gouw AA, Alsema AM, Tijms BM, Borta A, Scheltens P, Stam CJ, van der Flier WM. EEG spectral analysis as a putative early prognostic biomarker in nondemented, amyloid positive subjects. Neurobiology of Aging. 57: 133-142. PMID 28646686 DOI: 10.1016/j.neurobiolaging.2017.05.017  0.84
2017 van Loenhoud AC, Wink AM, Groot C, Verfaillie SCJ, Twisk J, Barkhof F, van Berckel B, Scheltens P, van der Flier WM, Ossenkoppele R. A neuroimaging approach to capture cognitive reserve: Application to Alzheimer's disease. Human Brain Mapping. PMID 28631336 DOI: 10.1002/hbm.23695  1
2017 Engelborghs S, Niemantsverdriet E, Struyfs H, Blennow K, Brouns R, Comabella M, Dujmovic I, van der Flier W, Frölich L, Galimberti D, Gnanapavan S, Hemmer B, Hoff E, Hort J, Iacobaeus E, ... ... Scheltens P, et al. Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimer's & Dementia (Amsterdam, Netherlands). 8: 111-126. PMID 28603768 DOI: 10.1016/j.dadm.2017.04.007  0.72
2017 Babapour Mofrad R, Bouwman FH, Slot RER, Timmers T, van der Flier WM, Scheltens P, Teunissen CE. Lumbar puncture in patients with neurologic conditions. Alzheimer's & Dementia (Amsterdam, Netherlands). 8: 108-110. PMID 28603767 DOI: 10.1016/j.dadm.2017.04.008  0.84
2017 Bridel C, Hoffmann T, Meyer A, Durieux S, Koel-Simmelink MA, Orth M, Scheltens P, Lues I, Teunissen CE. Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer's disease patients. Alzheimer's Research & Therapy. 9: 38. PMID 28587659 DOI: 10.1186/s13195-017-0266-6  0.72
2017 van Harten AC, Jongbloed W, Teunissen CE, Scheltens P, Veerhuis R, van der Flier WM. CSF ApoE predicts clinical progression in nondemented APOEε4 carriers. Neurobiology of Aging. PMID 28571653 DOI: 10.1016/j.neurobiolaging.2017.04.002  0.84
2017 Holstege H, van der Lee SJ, Hulsman M, Wong TH, van Rooij JG, Weiss M, Louwersheimer E, Wolters FJ, Amin N, Uitterlinden AG, Hofman A, Ikram MA, van Swieten JC, Meijers-Heijboer H, van der Flier WM, ... ... Scheltens P, et al. Characterization of pathogenic SORL1 genetic variants for association with Alzheimer's disease: a clinical interpretation strategy. European Journal of Human Genetics : Ejhg. PMID 28537274 DOI: 10.1038/ejhg.2017.87  0.84
2017 Rhodius-Meester HFM, Benedictus MR, Wattjes MP, Barkhof F, Scheltens P, Muller M, van der Flier WM. MRI Visual Ratings of Brain Atrophy and White Matter Hyperintensities across the Spectrum of Cognitive Decline Are Differently Affected by Age and Diagnosis. Frontiers in Aging Neuroscience. 9: 117. PMID 28536518 DOI: 10.3389/fnagi.2017.00117  1
2017 López ME, Engels MMA, van Straaten ECW, Bajo R, Delgado ML, Scheltens P, Hillebrand A, Stam CJ, Maestú F. MEG Beamformer-Based Reconstructions of Functional Networks in Mild Cognitive Impairment. Frontiers in Aging Neuroscience. 9: 107. PMID 28487647 DOI: 10.3389/fnagi.2017.00107  0.64
2017 Bos I, Vos SJ, Frölich L, Kornhuber J, Wiltfang J, Maier W, Peters O, Rüther E, Engelborghs S, Niemantsverdriet E, De Roeck EE, Tsolaki M, Freund-Levi Y, Johannsen P, Vandenberghe R, ... ... Scheltens P, et al. The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. Neurobiology of Aging. 56: 33-40. PMID 28482212 DOI: 10.1016/j.neurobiolaging.2017.03.034  0.6
2017 Harper L, Bouwman F, Burton EJ, Barkhof F, Scheltens P, O'Brien JT, Fox NC, Ridgway GR, Schott JM. Patterns of atrophy in pathologically confirmed dementias: a voxelwise analysis. Journal of Neurology, Neurosurgery, and Psychiatry. PMID 28473626 DOI: 10.1136/jnnp-2016-314978  1
2017 Jutten RJ, Peeters CFW, Leijdesdorff SMJ, Visser PJ, Maier AB, Terwee CB, Scheltens P, Sikkes SAM. Detecting functional decline from normal aging to dementia: Development and validation of a short version of the Amsterdam IADL Questionnaire. Alzheimer's & Dementia (Amsterdam, Netherlands). 8: 26-35. PMID 28462387 DOI: 10.1016/j.dadm.2017.03.002  0.64
2017 Gossink FT, Vijverberg EG, Krudop W, Scheltens P, Stek ML, Pijnenburg YA, Dols A. Psychosis in behavioral variant frontotemporal dementia. Neuropsychiatric Disease and Treatment. 13: 1099-1106. PMID 28458550 DOI: 10.2147/NDT.S127863  0.56
2017 Boomsma JMF, Exalto LG, Barkhof F, van den Berg E, de Bresser J, Heinen R, Koek HL, Prins ND, Scheltens P, Weinstein HC, van der Flier WM, Biessels GJ. Vascular Cognitive Impairment in a Memory Clinic Population: Rationale and Design of the "Utrecht-Amsterdam Clinical Features and Prognosis in Vascular Cognitive Impairment" (TRACE-VCI) Study. Jmir Research Protocols. 6: e60. PMID 28428166 DOI: 10.2196/resprot.6864  1
2017 Scheltens NME, Tijms BM, Koene T, Barkhof F, Teunissen CE, Wolfsgruber S, Wagner M, Kornhuber J, Peters O, Cohn-Sheehy BI, Rabinovici GD, Miller BL, Kramer JH, Scheltens P, van der Flier WM, et al. Cognitive subtypes of probable Alzheimer's disease robustly identified in four cohorts. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 28427934 DOI: 10.1016/j.jalz.2017.03.002  1
2017 Golla SS, Timmers T, Ossenkoppele R, Groot C, Verfaillie S, Scheltens P, van der Flier WM, Schwarte L, Mintun MA, Devous M, Schuit RC, Windhorst AD, Lammertsma AA, Boellaard R, van Berckel BN, et al. Quantification of Tau Load Using [(18)F]AV1451 PET. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 28374171 DOI: 10.1007/s11307-017-1080-z  0.84
2017 Mo Y, Stromswold J, Wilson K, Holder D, Sur C, Laterza O, Savage MJ, Struyk A, Scheltens P, Teunissen CE, Burke J, Macaulay SL, Bråthen G, Sando SB, White LR, et al. A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging. Alzheimer's & Dementia (Amsterdam, Netherlands). 6: 201-209. PMID 28349119 DOI: 10.1016/j.dadm.2017.02.004  0.72
2017 Vijverberg EG, Dols A, Krudop WA, Del Campo Milan M, Kerssens CJ, Gossink F, Prins ND, Stek ML, Scheltens P, Teunissen CE, Pijnenburg YA. Cerebrospinal fluid biomarker examination as a tool to discriminate behavioral variant frontotemporal dementia from primary psychiatric disorders. Alzheimer's & Dementia (Amsterdam, Netherlands). 7: 99-106. PMID 28337476 DOI: 10.1016/j.dadm.2017.01.009  0.72
2017 Yu M, Engels MM, Hillebrand A, van Straaten EC, Gouw AA, Teunissen C, van der Flier WM, Scheltens P, Stam CJ. Selective impairment of hippocampus and posterior hub areas in Alzheimer's disease: an MEG-based multiplex network study. Brain : a Journal of Neurology. PMID 28334883 DOI: 10.1093/brain/awx050  0.84
2017 Tijms BM, Bertens D, Slot RE, Gouw AA, Teunissen CE, Scheltens P, van der Flier WM, Visser PJ. Low normal CSF Aβ42 levels predict clinical progression in non-demented subjects. Annals of Neurology. PMID 28318059 DOI: 10.1002/ana.24921  0.84
2017 Ten Kate M, Barkhof F, Boccardi M, Visser PJ, Jack CR, Lovblad KO, Frisoni GB, Scheltens P. Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging. 52: 167-182.e1. PMID 28317647 DOI: 10.1016/j.neurobiolaging.2016.05.024  1
2017 Crutch SJ, Schott JM, Rabinovici GD, Murray M, Snowden JS, van der Flier WM, Dickerson BC, Vandenberghe R, Ahmed S, Bak TH, Boeve BF, Butler C, Cappa SF, Ceccaldi M, de Souza LC, ... ... Scheltens P, et al. Consensus classification of posterior cortical atrophy. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 28259709 DOI: 10.1016/j.jalz.2017.01.014  0.84
2017 de Wilde A, van Maurik IS, Kunneman M, Bouwman F, Zwan M, Willemse EA, Biessels GJ, Minkman M, Pel R, Schoonenboom NS, Smets EM, Wattjes MP, Barkhof F, Stephens A, van Lier EJ, ... ... Scheltens P, et al. Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design. Alzheimer's & Dementia (Amsterdam, Netherlands). 6: 143-151. PMID 28239639 DOI: 10.1016/j.dadm.2017.01.003  1
2017 Handels RL, Vos SJ, Kramberger MG, Jelic V, Blennow K, van Buchem M, van der Flier W, Freund-Levi Y, Hampel H, Olde Rikkert M, Oleksik A, Pirtosek Z, Scheltens P, Soininen H, Teunissen C, et al. Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 28216393 DOI: 10.1016/j.jalz.2016.12.015  0.52
2017 Bertens D, Tijms BM, Scheltens P, Teunissen CE, Visser PJ. Unbiased estimates of cerebrospinal fluid β-amyloid 1-42 cutoffs in a large memory clinic population. Alzheimer's Research & Therapy. 9: 8. PMID 28193256 DOI: 10.1186/s13195-016-0233-7  0.76
2017 Hooghiemstra AM, Ramakers IH, Sistermans N, Pijnenburg YA, Aalten P, Hamel RE, Melis RJ, Verhey FR, Olde Rikkert MG, Scheltens P, van der Flier WM. Gait Speed and Grip Strength Reflect Cognitive Impairment and Are Modestly Related to Incident Cognitive Decline in Memory Clinic Patients With Subjective Cognitive Decline and Mild Cognitive Impairment: Findings From the 4C Study. The Journals of Gerontology. Series a, Biological Sciences and Medical Sciences. PMID 28177065 DOI: 10.1093/gerona/glx003  0.84
2017 Zwan MD, Bouwman FH, Konijnenberg E, van der Flier WM, Lammertsma AA, Verhey FR, Aalten P, van Berckel BN, Scheltens P. Diagnostic impact of [(18)F]flutemetamol PET in early-onset dementia. Alzheimer's Research & Therapy. 9: 2. PMID 28093088 DOI: 10.1186/s13195-016-0228-4  0.84
2017 Claus JJ, Staekenborg SS, Holl DC, Roorda JJ, Schuur J, Koster P, Tielkes CE, Scheltens P. Practical use of visual medial temporal lobe atrophy cut-off scores in Alzheimer's disease: Validation in a large memory clinic population. European Radiology. PMID 28083697 DOI: 10.1007/s00330-016-4726-3  0.76
2017 van Waalwijk van Doorn LJ, Gispert JD, Kuiperij HB, Claassen JA, Arighi A, Baldeiras I, Blennow K, Bozzali M, Castelo-Branco M, Cavedo E, Emek-Savaş DD, Eren E, Eusebi P, Farotti L, Fenoglio C, ... ... Scheltens P, et al. Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. Journal of Alzheimer's Disease : Jad. PMID 28059783 DOI: 10.3233/JAD-160668  0.52
2016 Scheltens NME, Kuyper IS, Boellaard R, Barkhof F, Teunissen CE, Broersen LM, Lansbergen MM, van der Flier WM, van Berckel BNM, Scheltens P. Design of the NL-ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease. Alzheimer's & Dementia (New York, N. Y.). 2: 233-240. PMID 29067310 DOI: 10.1016/j.trci.2016.07.004  1
2016 Verfaillie SC, Tijms B, Versteeg A, Benedictus MR, Bouwman FH, Scheltens P, Barkhof F, Vrenken H, van der Flier WM. Thinner temporal and parietal cortex is related to incident clinical progression to dementia in patients with subjective cognitive decline. Alzheimer's & Dementia (Amsterdam, Netherlands). 5: 43-52. PMID 28054027 DOI: 10.1016/j.dadm.2016.10.007  1
2016 Slot RE, Van Harten AC, Kester MI, Jongbloed W, Bouwman FH, Teunissen CE, Scheltens P, Veerhuis R, van der Flier WM. Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer's Disease in Non-Demented Elderly. Journal of Alzheimer's Disease : Jad. PMID 28035918 DOI: 10.3233/JAD-151068  0.84
2016 Leijenaar JF, Scheltens P. From corticocentrism to leucocentrism or both. Brain : a Journal of Neurology. PMID 28007999 DOI: 10.1093/brain/aww311  0.48
2016 Jokinen H, Melkas S, Madureira S, Verdelho A, Ferro JM, Fazekas F, Schmidt R, Scheltens P, Barkhof F, Wardlaw JM, Inzitari D, Pantoni L, Erkinjuntti T. Cognitive reserve moderates long-term cognitive and functional outcome in cerebral small vessel disease. Journal of Neurology, Neurosurgery, and Psychiatry. 87: 1296-1302. PMID 27951523 DOI: 10.1136/jnnp-2016-313914  1
2016 Louwersheimer E, Cohn-Hokke PE, Pijnenburg YA, Weiss MM, Sistermans EA, Rozemuller AJ, Hulsman M, van Swieten JC, van Duijn CM, Barkhof F, Koene T, Scheltens P, Van der Flier WM, Holstege H. Rare Genetic Variant in SORL1 May Increase Penetrance of Alzheimer's Disease in a Family with Several Generations of APOE-ɛ4 Homozygosity. Journal of Alzheimer's Disease : Jad. PMID 27911290 DOI: 10.3233/JAD-160091  1
2016 Liao W, Hamel RE, Olde Rikkert MG, Oosterveld SM, Aalten P, Verhey FR, Scheltens P, Sistermans N, Pijnenburg YA, van der Flier WM, Ramakers IH, Melis RJ. A profile of The Clinical Course of Cognition and Comorbidity in Mild Cognitive Impairment and Dementia Study (The 4C study): two complementary longitudinal, clinical cohorts in the Netherlands. Bmc Neurology. 16: 242. PMID 27884130 DOI: 10.1186/s12883-016-0750-9  0.84
2016 van Straaten EC, de Waal H, Lansbergen MM, Scheltens P, Maestu F, Nowak R, Hillebrand A, Stam CJ. Magnetoencephalography for the Detection of Intervention Effects of a Specific Nutrient Combination in Patients with Mild Alzheimer's Disease: Results from an Exploratory Double-Blind, Randomized, Controlled Study. Frontiers in Neurology. 7: 161. PMID 27799918 DOI: 10.3389/fneur.2016.00161  0.64
2016 Dauwan M, van der Zande JJ, van Dellen E, Sommer IE, Scheltens P, Lemstra AW, Stam CJ. Random forest to differentiate dementia with Lewy bodies from Alzheimer's disease. Alzheimer's & Dementia (Amsterdam, Netherlands). 4: 99-106. PMID 27722196 DOI: 10.1016/j.dadm.2016.07.003  0.64
2016 Jansen WJ, Handels RL, Visser PJ, Aalten P, Bouwman F, Claassen J, van Domburg P, Hoff E, Hoogmoed J, Leentjens AF, Rikkert MO, Oleksik AM, Smid M, Scheltens P, Wolfs C, et al. The Diagnostic and Prognostic Value of Neuropsychological Assessment in Memory Clinic Patients. Journal of Alzheimer's Disease : Jad. PMID 27716658 DOI: 10.3233/JAD-160126  0.52
2016 Leeuwis AE, Benedictus MR, Kuijer JP, Binnewijzend MA, Hooghiemstra AM, Verfaillie SC, Koene T, Scheltens P, Barkhof F, Prins ND, van der Flier WM. Lower cerebral blood flow is associated with impairment in multiple cognitive domains in Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 27693109 DOI: 10.1016/j.jalz.2016.08.013  1
2016 Hafkemeijer A, Möller C, Dopper EG, Jiskoot LC, van den Berg-Huysmans AA, van Swieten JC, van der Flier WM, Vrenken H, Pijnenburg YA, Barkhof F, Scheltens P, van der Grond J, Rombouts SA. A Longitudinal Study on Resting State Functional Connectivity in Behavioral Variant Frontotemporal Dementia and Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. PMID 27662284 DOI: 10.3233/JAD-150695  1
2016 Cummings J, Aisen PS, DuBois B, Frölich L, Jack CR, Jones RW, Morris JC, Raskin J, Dowsett SA, Scheltens P. Drug development in Alzheimer's disease: the path to 2025. Alzheimer's Research & Therapy. 8: 39. PMID 27646601 DOI: 10.1186/s13195-016-0207-9  1
2016 Fuermaier AB, Piersma D, de Waard D, Davidse RJ, de Groot J, Doumen MJ, Bredewoud RA, Claesen R, Lemstra AW, Scheltens P, Vermeeren A, Ponds R, Verhey F, Brouwer WH, Tucha O. Assessing fitness to drive - A validation study on patients with Mild Cognitive Impairment. Traffic Injury Prevention. 0. PMID 27623685 DOI: 10.1080/15389588.2016.1232809  0.64
2016 Collij LE, Heeman F, Kuijer JP, Ossenkoppele R, Benedictus MR, Möller C, Verfaillie SC, Sanz-Arigita EJ, van Berckel BN, van der Flier WM, Scheltens P, Barkhof F, Wink AM. Application of Machine Learning to Arterial Spin Labeling in Mild Cognitive Impairment and Alzheimer Disease. Radiology. 152703. PMID 27383395 DOI: 10.1148/radiol.2016152703  1
2016 Madureira S, Verdelho A, Moleiro C, Santos C, Scheltens P, Gouw A, Ferro J. White Matter Changes and Cognitive Decline in a Ten-Year Follow-Up Period: A Pilot Study on a Single-Center Cohort from the Leukoaraiosis and Disability Study. Dementia and Geriatric Cognitive Disorders. 41: 303-313. PMID 27380560 DOI: 10.1159/000447121  0.36
2016 Vijverberg EG, Wattjes MP, Dols A, Krudop WA, Möller C, Peters A, Kerssens CJ, Gossink F, Prins ND, Stek ML, Scheltens P, van Berckel BN, Barkhof F, Pijnenburg YA. Diagnostic Accuracy of MRI and Additional [18F]FDG-PET for Behavioral Variant Frontotemporal Dementia in Patients with Late Onset Behavioral Changes. Journal of Alzheimer's Disease : Jad. PMID 27372646 DOI: 10.3233/JAD-160285  1
2016 Jack CR, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, Hampel H, Jagust WJ, Johnson KA, Knopman DS, Petersen RC, Scheltens P, Sperling RA, Dubois B. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. PMID 27371494 DOI: 10.1212/WNL.0000000000002923  1
2016 Chételat G, Ossenkoppele R, Villemagne VL, Perrotin A, Landeau B, Mézenge F, Jagust WJ, Dore V, Miller BL, Egret S, Seeley WW, van der Flier WM, La Joie R, Ames D, van Berckel BN, ... Scheltens P, et al. Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. Brain : a Journal of Neurology. PMID 27357349 DOI: 10.1093/brain/aww159  1
2016 Benedictus MR, Leeuwis AE, Binnewijzend MA, Kuijer JP, Scheltens P, Barkhof F, van der Flier WM, Prins ND. Lower cerebral blood flow is associated with faster cognitive decline in Alzheimer's disease. European Radiology. PMID 27334014 DOI: 10.1007/s00330-016-4450-z  1
2016 Sassi C, Nalls MA, Ridge PG, Gibbs JR, Ding J, Lupton MK, Troakes C, Lunnon K, Al-Sarraj S, Brown KS, Medway C, Clement N, Lord J, Turton J, Bras J, ... ... Scheltens P, et al. ABCA7 p.G215S as potential protective factor for Alzheimer's disease. Neurobiology of Aging. PMID 27289440 DOI: 10.1016/j.neurobiolaging.2016.04.004  1
2016 Cohn-Hokke PE, Holstege H, Weiss MM, van der Flier WM, Barkhof F, Sistermans EA, Pijnenburg YA, van Swieten JC, Meijers-Heijboer H, Scheltens P. A novel CCM2 variant in a family with non-progressive cognitive complaints and cerebral microbleeds. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. PMID 27277535 DOI: 10.1002/ajmg.b.32468  1
2016 Engels MM, Hillebrand A, van der Flier WM, Stam CJ, Scheltens P, van Straaten EC. Slowing of Hippocampal Activity Correlates with Cognitive Decline in Early Onset Alzheimer's Disease. An MEG Study with Virtual Electrodes. Frontiers in Human Neuroscience. 10: 238. PMID 27242496 DOI: 10.3389/fnhum.2016.00238  0.84
2016 Kerssens CJ, Krudop WA, Prins ND, van Berckel BN, Rozemuller A, Seeley WW, Scheltens P, Stek ML, Pijnenburg YA. Schizophrenia as a mimic of behavioral variant frontotemporal dementia. Neurocase. 1-4. PMID 27223596 DOI: 10.1080/13554794.2016.1187178  1
2016 Vandenberghe R, Rinne JO, Boada M, Katayama S, Scheltens P, Vellas B, Tuchman M, Gass A, Fiebach JB, Hill D, Lobello K, Li D, McRae T, Lucas P, Evans I, et al. Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials. Alzheimer's Research & Therapy. 8: 18. PMID 27176461 DOI: 10.1186/s13195-016-0189-7  0.56
2016 Vijverberg EG, Dols A, Krudop WA, Peters A, Kerssens CJ, van Berckel BN, Wattjes MP, Barkhof F, Gossink F, Prins ND, Stek ML, Scheltens P, Pijnenburg YA. Diagnostic Accuracy of the Frontotemporal Dementia Consensus Criteria in the Late-Onset Frontal Lobe Syndrome. Dementia and Geriatric Cognitive Disorders. 41: 210-9. PMID 27160162 DOI: 10.1159/000444849  1
2016 Konijnenberg E, Fereshtehnejad SM, Kate MT, Eriksdotter M, Scheltens P, Johannsen P, Waldemar G, Visser PJ. Early-Onset Dementia: Frequency, Diagnostic Procedures, and Quality Indicators in Three European Tertiary Referral Centers. Alzheimer Disease and Associated Disorders. PMID 27158877 DOI: 10.1097/WAD.0000000000000152  0.52
2016 Staekenborg SS, Pijnenburg YA, Lemstra AW, Scheltens P, Vd Flier WM. Dementia and Rapid Mortality: Who is at Risk? Journal of Alzheimer's Disease : Jad. PMID 27104894 DOI: 10.3233/JAD-151063  0.76
2016 Dauwan M, van Dellen E, van Boxtel L, van Straaten EC, de Waal H, Lemstra AW, Gouw AA, van der Flier WM, Scheltens P, Sommer IE, Stam CJ. EEG-directed connectivity from posterior brain regions is decreased in dementia with Lewy bodies: a comparison with Alzheimer's disease and controls. Neurobiology of Aging. 41: 122-9. PMID 27103525 DOI: 10.1016/j.neurobiolaging.2016.02.017  0.84
2016 Janssen N, Handels RL, Koehler S, Ramakers IH, Hamel RE, Olde Rikkert MG, Scheltens P, Bouwman FH, van der Flier WM, Wolfs CA, de Vugt ME, Evers SM, Verhey FR. Combinations of Service Use Types of People With Early Cognitive Disorders. Journal of the American Medical Directors Association. PMID 27073042 DOI: 10.1016/j.jamda.2016.02.034  0.84
2016 Handels RL, Joore MA, Vos SJ, Aalten P, Ramakers IH, Rikkert MO, Scheltens P, Jansen WJ, Visser PJ, van Berckel BM, van Domburg P, Smid M, Hoff E, Hoogmoed J, Bouwman F, et al. Added Prognostic Value of Cerebrospinal Fluid Biomarkers in Predicting Decline in Memory Clinic Patients in a Prospective Cohort. Journal of Alzheimer's Disease : Jad. PMID 27031483 DOI: 10.3233/JAD-151120  0.52
2016 Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K, Broich K, Cavedo E, Crutch S, Dartigues JF, Duyckaerts C, et al. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 12: 292-323. PMID 27012484 DOI: 10.1016/j.jalz.2016.02.002  0.8
2016 Schott JM, Crutch SJ, Carrasquillo MM, Uphill J, Shakespeare TJ, Ryan NS, Yong KX, Lehmann M, Ertekin-Taner N, Graff-Radford NR, Boeve BF, Murray ME, Khan QU, Petersen RC, Dickson DW, ... ... Scheltens P, et al. Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 26993346 DOI: 10.1016/j.jalz.2016.01.010  0.84
2016 Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, Cedazo-Minguez A, Dubois B, Edvardsson D, Feldman H, Fratiglioni L, Frisoni GB, Gauthier S, Georges J, Graff C, ... ... Scheltens P, et al. Defeating Alzheimer's disease and other dementias: a priority for European science and society. The Lancet. Neurology. 15: 455-532. PMID 26987701 DOI: 10.1016/S1474-4422(16)00062-4  1
2016 Gossink FT, Dols A, Krudop WA, Sikkes SA, Kerssens CJ, Prins ND, Scheltens P, Stek ML, Pijnenburg YA. Formal Psychiatric Disorders are not Overrepresented in Behavioral Variant Frontotemporal Dementia. Journal of Alzheimer's Disease : Jad. PMID 26967225 DOI: 10.3233/JAD-151198  1
2016 Harper L, Fumagalli GG, Barkhof F, Scheltens P, O'Brien JT, Bouwman F, Burton EJ, Rohrer JD, Fox NC, Ridgway GR, Schott JM. MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases. Brain : a Journal of Neurology. PMID 26936938 DOI: 10.1093/brain/aww005  1
2016 Louwersheimer E, Wolfsgruber S, Espinosa A, Lacour A, Heilmann-Heimbach S, Alegret M, Hernández I, Rosende-Roca M, Tárraga L, Boada M, Kornhuber J, Peters O, Frölich L, Hüll M, Rüther E, ... ... Scheltens P, et al. Alzheimer's disease risk variants modulate endophenotypes in mild cognitive impairment. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 26921674 DOI: 10.1016/j.jalz.2016.01.006  1
2016 Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM. Alzheimer's disease. Lancet (London, England). PMID 26921134 DOI: 10.1016/S0140-6736(15)01124-1  0.84
2016 Louwersheimer E, Keulen MA, Steenwijk MD, Wattjes MP, Jiskoot LC, Vrenken H, Teunissen CE, van Berckel BN, van der Flier WM, Scheltens P, van Swieten JC, Pijnenburg YA. Heterogeneous Language Profiles in Patients with Primary Progressive Aphasiadue to Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. PMID 26890751 DOI: 10.3233/JAD-150812  0.84
2016 Möller C, Hafkemeijer A, Pijnenburg YA, Rombouts SA, van der Grond J, Dopper E, van Swieten J, Versteeg A, Steenwijk MD, Barkhof F, Scheltens P, Vrenken H, van der Flier WM. Different patterns of cortical gray matter loss over time in behavioral variant frontotemporal dementia and Alzheimer's disease. Neurobiology of Aging. 38: 21-31. PMID 26827640 DOI: 10.1016/j.neurobiolaging.2015.10.020  1
2016 Claus JJ, Staekenborg SS, Roorda JJ, Stevens M, Herderschee D, Maarschalkerweerd WV, Schuurmans L, Tielkes CE, Koster P, Bavinck C, Scheltens P. Low Prevalence of Mixed Dementia in a Cohort of 2, 000 Elderly Patients in a Memory Clinic Setting. Journal of Alzheimer's Disease : Jad. PMID 26757192 DOI: 10.3233/JAD-150796  1
2016 van Waalwijk van Doorn LJ, Koel-Simmelink MJ, Haußmann U, Klafki H, Struyfs H, Linning P, Knölker HJ, Twaalfhoven H, Kuiperij HB, Engelborghs S, Scheltens P, Verbeek MM, Vanmechelen E, Wiltfang J, Teunissen CE. Validation of soluble APP assays as diagnostic CSF biomarkers for neurodegenerative diseases. Journal of Neurochemistry. PMID 26748905 DOI: 10.1111/jnc.13527  1
2016 Rosenberger AF, Morrema TH, Gerritsen WH, van Haastert ES, Snkhchyan H, Hilhorst R, Rozemuller AJ, Scheltens P, van der Vies SM, Hoozemans JJ. Increased occurrence of protein kinase CK2 in astrocytes in Alzheimer's disease pathology. Journal of Neuroinflammation. 13: 4. PMID 26732432 DOI: 10.1186/s12974-015-0470-x  1
2015 Pijnenburg YA, Verwey NA, van der Flier WM, Scheltens P, Teunissen CE. Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes. Alzheimer's & Dementia (Amsterdam, Netherlands). 1: 505-12. PMID 27239528 DOI: 10.1016/j.dadm.2015.11.001  0.84
2015 Del Campo Milan M, Zuroff L, Jimenez CR, Scheltens P, Teunissen CE. Can agrin cerebrospinal fluid concentration be used as an early biomarker for Alzheimer's disease? Alzheimer's & Dementia (Amsterdam, Netherlands). 1: 75-80. PMID 27239494 DOI: 10.1016/j.dadm.2014.11.008  0.72
2015 van Duinkerken E, Ijzerman RG, Klein M, Moll AC, Snoek FJ, Scheltens P, Pouwels PJ, Barkhof F, Diamant M, Tijms BM. Disrupted subject-specific gray matter network properties and cognitive dysfunction in type 1 diabetes patients with and without proliferative retinopathy. Human Brain Mapping. PMID 26700243 DOI: 10.1002/hbm.23096  1
2015 Hafkemeijer A, Möller C, Dopper EG, Jiskoot LC, van den Berg-Huysmans AA, van Swieten JC, van der Flier WM, Vrenken H, Pijnenburg YA, Barkhof F, Scheltens P, van der Grond J, Rombouts SA. Differences in structural covariance brain networks between behavioral variant frontotemporal dementia and Alzheimer's disease. Human Brain Mapping. PMID 26660857 DOI: 10.1002/hbm.23081  1
2015 Möller C, Pijnenburg YA, van der Flier WM, Versteeg A, Tijms B, de Munck JC, Hafkemeijer A, Rombouts SA, van der Grond J, van Swieten J, Dopper E, Scheltens P, Barkhof F, Vrenken H, Wink AM. Alzheimer Disease and Behavioral Variant Frontotemporal Dementia: Automatic Classification Based on Cortical Atrophy for Single-Subject Diagnosis. Radiology. 150220. PMID 26653846 DOI: 10.1148/radiol.2015150220  1
2015 Guerreiro R, Escott-Price V, Darwent L, Parkkinen L, Ansorge O, Hernandez DG, Nalls MA, Clark L, Honig L, Marder K, van der Flier W, Holstege H, Louwersheimer E, Lemstra A, Scheltens P, et al. Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. Neurobiology of Aging. PMID 26643944 DOI: 10.1016/j.neurobiolaging.2015.10.028  1
2015 Zwan MD, Villemagne VL, Doré V, Buckley R, Bourgeat P, Veljanoski R, Salvado O, Williams R, Margison L, Rembach A, Macaulay SL, Martins R, Ames D, van der Flier WM, Ellis KA, ... Scheltens P, et al. Subjective Memory Complaints in APOEɛ4 Carriers are Associated with High Amyloid-β Burden. Journal of Alzheimer's Disease : Jad. PMID 26639956 DOI: 10.3233/JAD-150446  1
2015 Groot C, Hooghiemstra AM, Raijmakers PG, Berckel BN, Scheltens P, Scherder EJ, Flieram WM, Ossenkoppele R. The Effect of Physical Activity on Cognitive Function in Patients with Dementia: A Meta-Analysis of Randomized Control Trials. Ageing Research Reviews. PMID 26607411 DOI: 10.1016/j.arr.2015.11.005  0.76
2015 Viswanathan A, Greenberg SM, Scheltens P. Role of Vascular Disease in Alzheimer-Like Progressive Cognitive Impairment. Stroke; a Journal of Cerebral Circulation. PMID 26604252 DOI: 10.1161/STROKEAHA.115.009010  1
2015 Möller C, Hafkemeijer A, Pijnenburg YA, Rombouts SA, van der Grond J, Dopper E, van Swieten J, Versteeg A, Pouwels PJ, Barkhof F, Scheltens P, Vrenken H, van der Flier WM. Joint assessment of white matter integrity, cortical and subcortical atrophy to distinguish AD from behavioral variant FTD: A two-center study. Neuroimage. Clinical. 9: 418-29. PMID 26594624 DOI: 10.1016/j.nicl.2015.08.022  1
2015 Rhodius-Meester HF, Koikkalainen J, Mattila J, Teunissen CE, Barkhof F, Lemstra AW, Scheltens P, Lötjönen J, van der Flier WM. Integrating Biomarkers for Underlying Alzheimer's Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers. Journal of Alzheimer's Disease : Jad. PMID 26577521 DOI: 10.3233/JAD-150548  1
2015 Tijms BM, Kate MT, Wink AM, Visser PJ, Ecay M, Clerigue M, Estanga A, Garcia Sebastian M, Izagirre A, Villanua J, Martinez Lage P, van der Flier WM, Scheltens P, Sanz Arigita E, Barkhof F. Gray matter network disruptions and amyloid beta in cognitively normal adults. Neurobiology of Aging. PMID 26559882 DOI: 10.1016/j.neurobiolaging.2015.10.015  1
2015 Abheiden CN, van Doornik R, Aukes AM, van der Flier WM, Scheltens P, de Groot CJ. Hypertensive Disorders of Pregnancy Appear Not to Be Associated with Alzheimer's Disease Later in Life. Dementia and Geriatric Cognitive Disorders Extra. 5: 375-85. PMID 26557136 DOI: 10.1159/000439043  0.84
2015 Reijs BL, Teunissen CE, Goncharenko N, Betsou F, Blennow K, Baldeiras I, Brosseron F, Cavedo E, Fladby T, Froelich L, Gabryelewicz T, Gurvit H, Kapaki E, Koson P, Kulic L, ... ... Scheltens P, et al. The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. Frontiers in Neurology. 6: 216. PMID 26528237 DOI: 10.3389/fneur.2015.00216  1
2015 Rosenberger AF, Hilhorst R, Coart E, García Barrado L, Naji F, Rozemuller AJ, van der Flier WM, Scheltens P, Hoozemans JJ, van der Vies SM. Protein Kinase Activity Decreases with Higher Braak Stages of Alzheimer's Disease Pathology. Journal of Alzheimer's Disease : Jad. PMID 26519433 DOI: 10.3233/JAD-150429  1
2015 Krudop WA, Dols A, Kerssens CJ, Prins ND, Möller C, Schouws S, Barkhof F, van Berckel BN, Teunissen CE, van der Flier WM, Scheltens P, Sikkes SA, Stek ML, Pijnenburg YA. Impact of Imaging and Cerebrospinal Fluid Biomarkers on Behavioral Variant Frontotemporal Dementia Diagnosis within a Late-Onset Frontal Lobe Syndrome Cohort. Dementia and Geriatric Cognitive Disorders. 41: 16-26. PMID 26473985 DOI: 10.1159/000441023  1
2015 Hafkemeijer A, Möller C, Dopper EG, Jiskoot LC, Schouten TM, van Swieten JC, van der Flier WM, Vrenken H, Pijnenburg YA, Barkhof F, Scheltens P, van der Grond J, Rombouts SA. Resting state functional connectivity differences between behavioral variant frontotemporal dementia and Alzheimer's disease. Frontiers in Human Neuroscience. 9: 474. PMID 26441584 DOI: 10.3389/fnhum.2015.00474  1
2015 Adriaanse SM, Wink AM, Tijms BM, Ossenkoppele R, Verfaillie S, Lammertsma AA, Boellaard R, Scheltens P, van Berckel BN, Barkhof F. The association of glucose metabolism and eigenvector centrality in Alzheimer's disease. Brain Connectivity. PMID 26414628 DOI: 10.1089/brain.2014.0320  1
2015 van Harten AC, Mulders J, Scheltens P, van der Flier WM, Oudejans CB. Differential Expression of microRNA in Cerebrospinal Fluid as a Potential Novel Biomarker for Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. 47: 243-52. PMID 26402772 DOI: 10.3233/JAD-140075  1
2015 Duits FH, Hernandez-Guillamon M, Montaner J, Goos JD, Montañola A, Wattjes MP, Barkhof F, Scheltens P, Teunissen CE, van der Flier WM. Matrix Metalloproteinases in Alzheimer's Disease and Concurrent Cerebral Microbleeds. Journal of Alzheimer's Disease : Jad. PMID 26402072 DOI: 10.3233/JAD-143186  1
2015 Kester MI, Teunissen CE, Sutphen C, Herries EM, Ladenson JH, Xiong C, Scheltens P, van der Flier WM, Morris JC, Holtzman DM, Fagan AM. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort. Alzheimer's Research & Therapy. 7: 59. PMID 26383836 DOI: 10.1186/s13195-015-0142-1  1
2015 Duits FH, Martinez-Lage P, Paquet C, Engelborghs S, Lleó A, Hausner L, Molinuevo JL, Stomrud E, Farotti L, Ramakers IH, Tsolaki M, Skarsgård C, Åstrand R, Wallin A, Vyhnalek M, ... ... Scheltens P, et al. Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 26368321 DOI: 10.1016/j.jalz.2015.08.003  1
2015 Kester MI, Teunissen CE, Crimmins DL, Herries EM, Ladenson JH, Scheltens P, van der Flier WM, Morris JC, Holtzman DM, Fagan AM. Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease. Jama Neurology. 1-7. PMID 26366630 DOI: 10.1001/jamaneurol.2015.1867  1
2015 Morley JE, Morris JC, Berg-Weger M, Borson S, Carpenter BD, Del Campo N, Dubois B, Fargo K, Fitten LJ, Flaherty JH, Ganguli M, Grossberg GT, Malmstrom TK, Petersen RD, Rodriguez C, ... ... Scheltens P, et al. Brain Health: The Importance of Recognizing Cognitive Impairment: An IAGG Consensus Conference. Journal of the American Medical Directors Association. 16: 731-9. PMID 26315321 DOI: 10.1016/j.jamda.2015.06.017  1
2015 Engels MM, Stam CJ, van der Flier WM, Scheltens P, de Waal H, van Straaten EC. Declining functional connectivity and changing hub locations in Alzheimer's disease: an EEG study. Bmc Neurology. 15: 145. PMID 26289045 DOI: 10.1186/s12883-015-0400-7  1
2015 Ossenkoppele R, Cohn-Sheehy BI, La Joie R, Vogel JW, Möller C, Lehmann M, van Berckel BN, Seeley WW, Pijnenburg YA, Gorno-Tempini ML, Kramer JH, Barkhof F, Rosen HJ, van der Flier WM, Jagust WJ, ... ... Scheltens P, et al. Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease. Human Brain Mapping. PMID 26260856 DOI: 10.1002/hbm.22927  0.76
2015 Toledo JB, Zetterberg H, van Harten AC, Glodzik L, Martinez-Lage P, Bocchio-Chiavetto L, Rami L, Hansson O, Sperling R, Engelborghs S, Osorio RS, Vanderstichele H, Vandijck M, Hampel H, Teipl S, ... ... Scheltens P, et al. Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain : a Journal of Neurology. 138: 2701-15. PMID 26220940 DOI: 10.1093/brain/awv199  0.84
2015 van Dellen E, de Waal H, van der Flier WM, Lemstra AW, Slooter AJ, Smits LL, van Straaten EC, Stam CJ, Scheltens P. Loss of EEG Network Efficiency Is Related to Cognitive Impairment in Dementia With Lewy Bodies. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 26179663 DOI: 10.1002/mds.26309  1
2015 Benedictus MR, van Harten AC, Leeuwis AE, Koene T, Scheltens P, Barkhof F, Prins ND, van der Flier WM. White Matter Hyperintensities Relate to Clinical Progression in Subjective Cognitive Decline. Stroke; a Journal of Cerebral Circulation. 46: 2661-4. PMID 26173729 DOI: 10.1161/STROKEAHA.115.009475  1
2015 Ossenkoppele R, Pijnenburg YA, Perry DC, Cohn-Sheehy BI, Scheltens NM, Vogel JW, Kramer JH, van der Vlies AE, Joie RL, Rosen HJ, van der Flier WM, Grinberg LT, Rozemuller AJ, Huang EJ, van Berckel BN, ... ... Scheltens P, et al. The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. Brain : a Journal of Neurology. 138: 2732-49. PMID 26141491 DOI: 10.1093/brain/awv191  1
2015 Chouliaras L, Kenis G, Visser PJ, Scheltens P, Tsolaki M, Jones RW, Kehoe PG, Graff C, Girtler NG, Wallin ÅK, Rikkert MO, Spiru L, Elias-Sonnenschein LS, Ramakers IH, Pishva E, et al. DNMT3A moderates cognitive decline in subjects with mild cognitive impairment: replicated evidence from two mild cognitive impairment cohorts. Epigenomics. 7: 533-537. PMID 26111027 DOI: 10.2217/epi.15.22  1
2015 Krudop WA, Bosman S, Geurts JJ, Sikkes SA, Verwey NA, Stek ML, Scheltens P, Rozemuller AJ, Pijnenburg YA. Clinico-Pathological Correlations of the Frontal Lobe Syndrome: Results of a Large Brain Bank Study. Dementia and Geriatric Cognitive Disorders. 40: 121-9. PMID 26088035 DOI: 10.1159/000430460  1
2015 Binnewijzend MA, Benedictus MR, Kuijer JP, van der Flier WM, Teunissen CE, Prins ND, Wattjes MP, van Berckel BN, Scheltens P, Barkhof F. Cerebral perfusion in the predementia stages of Alzheimer's disease. European Radiology. PMID 26040647 DOI: 10.1007/s00330-015-3834-9  1
2015 Ossenkoppele R, Mattsson N, Teunissen CE, Barkhof F, Pijnenburg Y, Scheltens P, van der Flier WM, Rabinovici GD. Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. Neurobiology of Aging. 36: 2340-7. PMID 25990306 DOI: 10.1016/j.neurobiolaging.2015.04.011  1
2015 Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BN, Scheltens P, Visser PJ, Verfaillie SC, Zwan MD, Adriaanse SM, Lammertsma AA, Barkhof F, Jagust WJ, et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. Jama. 313: 1939-49. PMID 25988463 DOI: 10.1001/jama.2015.4669  1
2015 Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, Visser PJ, Aalten P, Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, Baldeiras I, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. Jama. 313: 1924-38. PMID 25988462 DOI: 10.1001/jama.2015.4668  1
2015 Krudop WA, Kerssens CJ, Dols A, Prins ND, Möller C, Schouws S, van der Flier WM, Scheltens P, Sikkes S, Stek ML, Pijnenburg YA. Identifying bvFTD Within the Wide Spectrum of Late Onset Frontal Lobe Syndrome: A Clinical Approach. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. PMID 25921226 DOI: 10.1016/j.jagp.2015.04.002  1
2015 Yi HA, Möller C, Dieleman N, Bouwman FH, Barkhof F, Scheltens P, van der Flier WM, Vrenken H. Relation between subcortical grey matter atrophy and conversion from mild cognitive impairment to Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry. PMID 25904810 DOI: 10.1136/jnnp-2014-309105  1
2015 Verfaillie SC, Adriaanse SM, Binnewijzend MA, Benedictus MR, Ossenkoppele R, Wattjes MP, Pijnenburg YA, van der Flier WM, Lammertsma AA, Kuijer JP, Boellaard R, Scheltens P, van Berckel BN, Barkhof F. Cerebral perfusion and glucose metabolism in Alzheimer's disease and frontotemporal dementia: two sides of the same coin? European Radiology. PMID 25899416 DOI: 10.1007/s00330-015-3696-1  1
2015 Smits LL, Pijnenburg YA, van der Vlies AE, Koedam EL, Bouwman FH, Reuling IE, Scheltens P, van der Flier WM. Early onset APOE E4-negative Alzheimer's disease patients show faster cognitive decline on non-memory domains. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 25: 1010-7. PMID 25891378 DOI: 10.1016/j.euroneuro.2015.03.014  1
2015 Coart E, Barrado LG, Duits FH, Scheltens P, van der Flier WM, Teunissen CE, van der Vies SM, Burzykowski T. Correcting for the Absence of a Gold Standard Improves Diagnostic Accuracy of Biomarkers in Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. PMID 25869788 DOI: 10.3233/JAD-142886  1
2015 van der Lee SJ, Holstege H, Wong TH, Jakobsdottir J, Bis JC, Chouraki V, van Rooij JG, Grove ML, Smith AV, Amin N, Choi SH, Beiser AS, Garcia ME, van IJcken WF, Pijnenburg YA, ... ... Scheltens P, et al. PLD3 variants in population studies. Nature. 520: E2-3. PMID 25832410 DOI: 10.1038/nature14038  1
2015 Schmidt R, Hofer E, Bouwman FH, Buerger K, Cordonnier C, Fladby T, Galimberti D, Georges J, Heneka MT, Hort J, Laczó J, Molinuevo JL, O'Brien JT, Religa D, Scheltens P, et al. EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 22: 889-98. PMID 25808982 DOI: 10.1111/ene.12707  1
2015 Benedictus MR, Prins ND, Goos JD, Scheltens P, Barkhof F, van der Flier WM. Microbleeds, Mortality, and Stroke in Alzheimer Disease: The MISTRAL Study. Jama Neurology. 72: 539-45. PMID 25798556 DOI: 10.1001/jamaneurol.2015.14  1
2015 Scheltens NM, Galindo-Garre F, Pijnenburg YA, van der Vlies AE, Smits LL, Koene T, Teunissen CE, Barkhof F, Wattjes MP, Scheltens P, van der Flier WM. The identification of cognitive subtypes in Alzheimer's disease dementia using latent class analysis. Journal of Neurology, Neurosurgery, and Psychiatry. PMID 25783437 DOI: 10.1136/jnnp-2014-309582  1
2015 Exalto LG, van der Flier WM, van Boheemen CJ, Kappelle LJ, Vrenken H, Teunissen C, Koene T, Scheltens P, Biessels GJ. The metabolic syndrome in a memory clinic population: relation with clinical profile and prognosis. Journal of the Neurological Sciences. 351: 18-23. PMID 25748296 DOI: 10.1016/j.jns.2015.02.004  1
2015 Vos SJ, Verhey F, Frölich L, Kornhuber J, Wiltfang J, Maier W, Peters O, Rüther E, Nobili F, Morbelli S, Frisoni GB, Drzezga A, Didic M, van Berckel BN, Simmons A, ... ... Scheltens P, et al. Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain : a Journal of Neurology. 138: 1327-38. PMID 25693589 DOI: 10.1093/brain/awv029  1
2015 Prins ND, Scheltens P. White matter hyperintensities, cognitive impairment and dementia: an update. Nature Reviews. Neurology. 11: 157-65. PMID 25686760 DOI: 10.1038/nrneurol.2015.10  1
2015 Louwersheimer E, Ramirez A, Cruchaga C, Becker T, Kornhuber J, Peters O, Heilmann S, Wiltfang J, Jessen F, Visser PJ, Scheltens P, Pijnenburg YA, Teunissen CE, Barkhof F, van Swieten JC, et al. The influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease. Neurobiology of Aging. 36: 1605.e13-20. PMID 25659857 DOI: 10.1016/j.neurobiolaging.2014.12.007  1
2015 Bron EE, Smits M, van der Flier WM, Vrenken H, Barkhof F, Scheltens P, Papma JM, Steketee RM, Méndez Orellana C, Meijboom R, Pinto M, Meireles JR, Garrett C, Bastos-Leite AJ, Abdulkadir A, et al. Standardized evaluation of algorithms for computer-aided diagnosis of dementia based on structural MRI: the CADDementia challenge. Neuroimage. 111: 562-79. PMID 25652394 DOI: 10.1016/j.neuroimage.2015.01.048  1
2015 Prestia A, Caroli A, Wade SK, van der Flier WM, Ossenkoppele R, Van Berckel B, Barkhof F, Teunissen CE, Wall A, Carter SF, Schöll M, Choo IH, Nordberg A, Scheltens P, Frisoni GB. Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 25646957 DOI: 10.1016/j.jalz.2014.12.001  1
2015 Gossink FT, Dols A, Kerssens CJ, Krudop WA, Kerklaan BJ, Scheltens P, Stek ML, Pijnenburg YA. Psychiatric diagnoses underlying the phenocopy syndrome of behavioural variant frontotemporal dementia. Journal of Neurology, Neurosurgery, and Psychiatry. PMID 25618904 DOI: 10.1136/jnnp-2014-308284  1
2015 Koster N, Knol DL, Uitdehaag BM, Scheltens P, Sikkes SA. The sensitivity to change over time of the Amsterdam IADL Questionnaire(©) Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 25598195 DOI: 10.1016/j.jalz.2014.10.006  1
2015 Caroli A, Prestia A, Galluzzi S, Ferrari C, van der Flier WM, Ossenkoppele R, Van Berckel B, Barkhof F, Teunissen C, Wall AE, Carter SF, Schöll M, Choo IH, Grimmer T, Redolfi A, ... ... Scheltens P, et al. Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression. Neurology. 84: 508-15. PMID 25568301 DOI: 10.1212/WNL.0000000000001209  1
2015 Jochemsen HM, Muller M, Bots ML, Scheltens P, Vincken KL, Mali WP, van der Graaf Y, Geerlings MI. Arterial stiffness and progression of structural brain changes: The SMART-MR study. Neurology. 84: 448-55. PMID 25552578 DOI: 10.1212/WNL.0000000000001201  1
2015 Jongbloed W, Bruggink KA, Kester MI, Visser PJ, Scheltens P, Blankenstein MA, Verbeek MM, Teunissen CE, Veerhuis R. Amyloid-β oligomers relate to cognitive decline in Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 45: 35-43. PMID 25547634 DOI: 10.3233/JAD-142136  1
2015 Hall A, Mattila J, Koikkalainen J, Lötjonen J, Wolz R, Scheltens P, Frisoni G, Tsolaki M, Nobili F, Freund-Levi Y, Minthon L, Frölich L, Hampel H, Visser PJ, Soininen H. Predicting progression from cognitive impairment to Alzheimer's disease with the Disease State Index. Current Alzheimer Research. 12: 69-79. PMID 25523428  1
2015 Hamel R, Köhler S, Sistermans N, Koene T, Pijnenburg Y, van der Flier W, Scheltens P, Aalten P, Verhey F, Visser PJ, Ramakers I. The trajectory of cognitive decline in the pre-dementia phase in memory clinic visitors: findings from the 4C-MCI study. Psychological Medicine. 45: 1509-19. PMID 25407094 DOI: 10.1017/S0033291714002645  1
2015 Frederiksen KS, Verdelho A, Madureira S, Bäzner H, O'Brien JT, Fazekas F, Scheltens P, Schmidt R, Wallin A, Wahlund LO, Erkinjunttii T, Poggesi A, Pantoni L, Inzitari D, Waldemar G, et al. Physical activity in the elderly is associated with improved executive function and processing speed: the LADIS Study. International Journal of Geriatric Psychiatry. 30: 744-50. PMID 25363336 DOI: 10.1002/gps.4220  1
2015 Teunissen CE, van der Flier WM, Scheltens P, Duits A, Wijnstok N, Nijpels G, Dekker JM, Blankenstein RM, Heijboer AC. Serum leptin is not altered nor related to cognitive decline in Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 44: 809-13. PMID 25352450 DOI: 10.3233/JAD-141503  1
2015 Möller C, Dieleman N, van der Flier WM, Versteeg A, Pijnenburg Y, Scheltens P, Barkhof F, Vrenken H. More atrophy of deep gray matter structures in frontotemporal dementia compared to Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 44: 635-47. PMID 25322925 DOI: 10.3233/JAD-141230  1
2015 Olde Rikkert MG, Verhey FR, Blesa R, von Arnim CA, Bongers A, Harrison J, Sijben J, Scarpini E, Vandewoude MF, Vellas B, Witkamp R, Kamphuis PJ, Scheltens P. Tolerability and safety of Souvenaid in patients with mild Alzheimer's disease: results of multi-center, 24-week, open-label extension study. Journal of Alzheimer's Disease : Jad. 44: 471-80. PMID 25322923 DOI: 10.3233/JAD-141305  1
2015 Frisoni GB, Jack CR, Bocchetta M, Bauer C, Frederiksen KS, Liu Y, Preboske G, Swihart T, Blair M, Cavedo E, Grothe MJ, Lanfredi M, Martinez O, Nishikawa M, Portegies M, ... ... Scheltens P, et al. The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: evidence of validity. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 11: 111-25. PMID 25267715 DOI: 10.1016/j.jalz.2014.05.1756  1
2015 Jonker FA, Jonker C, Scheltens P, Scherder EJ. The role of the orbitofrontal cortex in cognition and behavior. Reviews in the Neurosciences. 26: 1-11. PMID 25252749 DOI: 10.1515/revneuro-2014-0043  1
2015 Smits LL, van Harten AC, Pijnenburg YA, Koedam EL, Bouwman FH, Sistermans N, Reuling IE, Prins ND, Lemstra AW, Scheltens P, van der Flier WM. Trajectories of cognitive decline in different types of dementia. Psychological Medicine. 45: 1051-9. PMID 25229325 DOI: 10.1017/S0033291714002153  1
2015 Douglas CM, Scheltens P. Rethinking biobanking and translational medicine in the Netherlands: how the research process stands to matter for patient care. European Journal of Human Genetics : Ejhg. 23: 736-8. PMID 25227145 DOI: 10.1038/ejhg.2014.186  1
2015 Jochemsen HM, van der Flier WM, Ashby EL, Teunissen CE, Jones RE, Wattjes MP, Scheltens P, Geerlings MI, Kehoe PG, Muller M. Angiotensin-converting enzyme in cerebrospinal fluid and risk of brain atrophy. Journal of Alzheimer's Disease : Jad. 44: 153-62. PMID 25201786 DOI: 10.3233/JAD-131496  1
2015 Duits FH, Prins ND, Lemstra AW, Pijnenburg YA, Bouwman FH, Teunissen CE, Scheltens P, van der Flier WM. Diagnostic impact of CSF biomarkers for Alzheimer's disease in a tertiary memory clinic. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 11: 523-32. PMID 25156643 DOI: 10.1016/j.jalz.2014.05.1753  1
2015 Bertens D, Knol DL, Scheltens P, Visser PJ. Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 11: 511-22. PMID 25150730 DOI: 10.1016/j.jalz.2014.05.1754  1
2015 van Rooden S, Doan NT, Versluis MJ, Goos JD, Webb AG, Oleksik AM, van der Flier WM, Scheltens P, Barkhof F, Weverling-Rynsburger AW, Blauw GJ, Reiber JH, van Buchem MA, Milles J, van der Grond J. 7T T₂*-weighted magnetic resonance imaging reveals cortical phase differences between early- and late-onset Alzheimer's disease. Neurobiology of Aging. 36: 20-6. PMID 25113794 DOI: 10.1016/j.neurobiolaging.2014.07.006  1
2015 Joling KJ, van Marwijk HW, Veldhuijzen AE, van der Horst HE, Scheltens P, Smit F, van Hout HP. The two-year incidence of depression and anxiety disorders in spousal caregivers of persons with dementia: who is at the greatest risk? The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 23: 293-303. PMID 24935785 DOI: 10.1016/j.jagp.2014.05.005  1
2015 Hooghiemstra AM, Eggermont LH, Scheltens P, van der Flier WM, Scherder EJ. The rest-activity rhythm and physical activity in early-onset dementia. Alzheimer Disease and Associated Disorders. 29: 45-9. PMID 24632989 DOI: 10.1097/WAD.0000000000000037  1
2015 Macfarlane MD, Looi JC, Walterfang M, Spulber G, Velakoulis D, Styner M, Crisby M, Orndahl E, Erkinjuntti T, Waldemar G, Garde E, Hennerici MG, Bäzner H, Blahak C, Wallin A, et al. Shape abnormalities of the caudate nucleus correlate with poorer gait and balance: results from a subset of the LADIS study. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 23: 59-71.e1. PMID 23916546 DOI: 10.1016/j.jagp.2013.04.011  1
2015 Rijpma A, Meulenbroek O, Van Hees AMJ, Sijben JWC, Vellas B, Shah RC, Bennett DA, Scheltens P, Olde Rikkert MGM. Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease Alzheimer's Research and Therapy. 7. DOI: 10.1186/s13195-015-0134-1  1
2015 Toledo JB, Zetterberg H, Van Harten AC, Glodzik L, Martinez-Lage P, Bocchio-Chiavetto L, Rami L, Hansson O, Sperling R, Engelborghs S, Osorio RS, Vanderstichele H, Vandijck M, Hampel H, Teipl S, ... ... Scheltens P, et al. Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects Brain. 138: 2701-2715. DOI: 10.1093/brain/awv199  1
2015 Pijnenburg YAL, Verwey NA, van der Flier WM, Scheltens P, Teunissen CE. Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring. 1: 505-512. DOI: 10.1016/j.dadm.2015.11.001  0.76
2015 Del Campo Milan M, Zuroff L, Jimenez CR, Scheltens P, Teunissen CE. Can agrin cerebrospinal fluid concentration be used as an early biomarker for Alzheimer's disease? Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring. 1: 75-80. DOI: 10.1016/j.dadm.2014.11.008  1
2014 van Straaten EC, Scheltens P, Gouw AA, Stam CJ. Eyes-closed task-free electroencephalography in clinical trials for Alzheimer's disease: an emerging method based upon brain dynamics. Alzheimer's Research & Therapy. 6: 86. PMID 25621017 DOI: 10.1186/s13195-014-0086-x  1
2014 Kvartsberg H, Duits FH, Ingelsson M, Andreasen N, Öhrfelt A, Andersson K, Brinkmalm G, Lannfelt L, Minthon L, Hansson O, Andreasson U, Teunissen CE, Scheltens P, Van der Flier WM, Zetterberg H, et al. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 25533203 DOI: 10.1016/j.jalz.2014.10.009  1
2014 van Rooden S, Buijs M, van Vliet ME, Versluis MJ, Webb AG, Oleksik AM, van de Wiel L, Middelkoop HA, Blauw GJ, Weverling-Rynsburger AW, Goos JD, van der Flier WM, Koene T, Scheltens P, Barkhof F, et al. Cortical phase changes measured using 7-T MRI in subjects with subjective cognitive impairment, and their association with cognitive function. Nmr in Biomedicine. PMID 25522735 DOI: 10.1002/nbm.3248  1
2014 Prins ND, van der Flier WA, Knol DL, Fox NC, Brashear HR, Nye JS, Barkhof F, Scheltens P. The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial. Alzheimer's Research & Therapy. 6: 47. PMID 25478019 DOI: 10.1186/alzrt275  1
2014 Cohn-Hokke PE, Wong TH, Rizzu P, Breedveld G, van der Flier WM, Scheltens P, Baas F, Heutink P, Meijers-Heijboer EJ, van Swieten JC, Pijnenburg YA. Mutation frequency of PRKAR1B and the major familial dementia genes in a Dutch early onset dementia cohort. Journal of Neurology. 261: 2085-92. PMID 25108559 DOI: 10.1007/s00415-014-7456-y  1
2014 Adriaanse SM, Binnewijzend MA, Ossenkoppele R, Tijms BM, van der Flier WM, Koene T, Smits LL, Wink AM, Scheltens P, van Berckel BN, Barkhof F. Widespread disruption of functional brain organization in early-onset Alzheimer's disease. Plos One. 9: e102995. PMID 25080229 DOI: 10.1371/journal.pone.0102995  1
2014 Ouwens DM, van Duinkerken E, Schoonenboom SN, Herzfeld de Wiza D, Klein M, van Golen L, Pouwels PJ, Barkhof F, Moll AC, Snoek FJ, Teunissen CE, Scheltens P, Diamant M. Cerebrospinal fluid levels of Alzheimer's disease biomarkers in middle-aged patients with type 1 diabetes. Diabetologia. 57: 2208-14. PMID 25034377 DOI: 10.1007/s00125-014-3333-6  1
2014 Ramirez A, van der Flier WM, Herold C, Ramonet D, Heilmann S, Lewczuk P, Popp J, Lacour A, Drichel D, Louwersheimer E, Kummer MP, Cruchaga C, Hoffmann P, Teunissen C, Holstege H, ... ... Scheltens P, et al. SUCLG2 identified as both a determinator of CSF Aβ1-42 levels and an attenuator of cognitive decline in Alzheimer's disease. Human Molecular Genetics. 23: 6644-58. PMID 25027320 DOI: 10.1093/hmg/ddu372  1
2014 Rosenberger AF, Rozemuller AJ, van der Flier WM, Scheltens P, van der Vies SM, Hoozemans JJ. Altered distribution of the EphA4 kinase in hippocampal brain tissue of patients with Alzheimer's disease correlates with pathology. Acta Neuropathologica Communications. 2: 79. PMID 25027113 DOI: 10.1186/s40478-014-0079-9  1
2014 Benedictus MR, Binnewijzend MA, Kuijer JP, Steenwijk MD, Versteeg A, Vrenken H, Scheltens P, Barkhof F, van der Flier WM, Prins ND. Brain volume and white matter hyperintensities as determinants of cerebral blood flow in Alzheimer's disease. Neurobiology of Aging. 35: 2665-70. PMID 25018106 DOI: 10.1016/j.neurobiolaging.2014.06.001  1
2014 Binnewijzend MA, Kuijer JP, van der Flier WM, Benedictus MR, Möller CM, Pijnenburg YA, Lemstra AW, Prins ND, Wattjes MP, van Berckel BN, Scheltens P, Barkhof F. Distinct perfusion patterns in Alzheimer's disease, frontotemporal dementia and dementia with Lewy bodies. European Radiology. 24: 2326-33. PMID 24996793 DOI: 10.1007/s00330-014-3172-3  1
2014 Boelaarts L, Scheltens P, de Jonghe J. Using magnetic resonance imaging in diagnosing dementia: a Dutch outpatient memory clinics survey. Dementia and Geriatric Cognitive Disorders. 38: 281-5. PMID 24994453 DOI: 10.1159/000363499  1
2014 Jochemsen HM, Teunissen CE, Ashby EL, van der Flier WM, Jones RE, Geerlings MI, Scheltens P, Kehoe PG, Muller M. The association of angiotensin-converting enzyme with biomarkers for Alzheimer's disease. Alzheimer's Research & Therapy. 6: 27. PMID 24987467 DOI: 10.1186/alzrt257  1
2014 Bras J, Guerreiro R, Darwent L, Parkkinen L, Ansorge O, Escott-Price V, Hernandez DG, Nalls MA, Clark LN, Honig LS, Marder K, Van Der Flier WM, Lemstra A, Scheltens P, Rogaeva E, et al. Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Human Molecular Genetics. 23: 6139-46. PMID 24973356 DOI: 10.1093/hmg/ddu334  1
2014 Vos SJ, Visser PJ, Verhey F, Aalten P, Knol D, Ramakers I, Scheltens P, Rikkert MG, Verbeek MM, Teunissen CE. Variability of CSF Alzheimer's disease biomarkers: implications for clinical practice. Plos One. 9: e100784. PMID 24959687 DOI: 10.1371/journal.pone.0100784  1
2014 Hartmann T, van Wijk N, Wurtman RJ, Olde Rikkert MG, Sijben JW, Soininen H, Vellas B, Scheltens P. A nutritional approach to ameliorate altered phospholipid metabolism in Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 41: 715-7. PMID 24898653 DOI: 10.3233/JAD-141137  1
2014 Zwan MD, Ossenkoppele R, Tolboom N, Beunders AJ, Kloet RW, Adriaanse SM, Boellaard R, Windhorst AD, Raijmakers P, Adams H, Lammertsma AA, Scheltens P, van der Flier WM, van Berckel BN. Comparison of simplified parametric methods for visual interpretation of 11C-Pittsburgh compound-B PET images. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 55: 1305-7. PMID 24898026 DOI: 10.2967/jnumed.114.139121  1
2014 Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, ... ... Scheltens P, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. The Lancet. Neurology. 13: 614-29. PMID 24849862 DOI: 10.1016/S1474-4422(14)70090-0  1
2014 Kester MI, Goos JD, Teunissen CE, Benedictus MR, Bouwman FH, Wattjes MP, Barkhof F, Scheltens P, van der Flier WM. Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers. Jama Neurology. 71: 855-62. PMID 24818585 DOI: 10.1001/jamaneurol.2014.754  1
2014 Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chételat G, Dubois B, Dufouil C, Ellis KA, van der Flier WM, Glodzik L, van Harten AC, de Leon MJ, McHugh P, Mielke MM, ... ... Scheltens P, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 10: 844-52. PMID 24798886 DOI: 10.1016/j.jalz.2014.01.001  1
2014 Ossenkoppele R, van der Flier WM, Verfaillie SC, Vrenken H, Versteeg A, van Schijndel RA, Sikkes SA, Twisk J, Adriaanse SM, Zwan MD, Boellaard R, Windhorst AD, Barkhof F, Scheltens P, Lammertsma AA, et al. Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions. Neurology. 82: 1768-75. PMID 24748672 DOI: 10.1212/WNL.0000000000000432  1
2014 Tijms BM, Yeung HM, Sikkes SA, Möller C, Smits LL, Stam CJ, Scheltens P, van der Flier WM, Barkhof F. Single-subject gray matter graph properties and their relationship with cognitive impairment in early- and late-onset Alzheimer's disease. Brain Connectivity. 4: 337-46. PMID 24735020 DOI: 10.1089/brain.2013.0209  1
2014 Poggesi A, Gouw A, van der Flier W, Pracucci G, Chabriat H, Erkinjuntti T, Fazekas F, Ferro JM, Blahak C, Langhorne P, O'Brien J, Schmidt R, Visser MC, Wahlund LO, Waldemar G, ... ... Scheltens P, et al. Neurological abnormalities predict disability: the LADIS (Leukoaraiosis And DISability) study. Journal of Neurology. 261: 1160-9. PMID 24723116 DOI: 10.1007/s00415-014-7332-9  1
2014 Duits FH, Teunissen CE, Bouwman FH, Visser PJ, Mattsson N, Zetterberg H, Blennow K, Hansson O, Minthon L, Andreasen N, Marcusson J, Wallin A, Rikkert MO, Tsolaki M, Parnetti L, ... ... Scheltens P, et al. The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean? Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 10: 713-723.e2. PMID 24721526 DOI: 10.1016/j.jalz.2013.12.023  1
2014 Zwan M, van Harten A, Ossenkoppele R, Bouwman F, Teunissen C, Adriaanse S, Lammertsma A, Scheltens P, van Berckel B, van der Flier W. Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort. Journal of Alzheimer's Disease : Jad. 41: 801-7. PMID 24705549 DOI: 10.3233/JAD-132561  1
2014 Oudega ML, van Exel E, Stek ML, Wattjes MP, van der Flier WM, Comijs HC, Dols A, Scheltens P, Barkhof F, Eikelenboom P, van den Heuvel OA. The structure of the geriatric depressed brain and response to electroconvulsive therapy. Psychiatry Research. 222: 1-9. PMID 24686000 DOI: 10.1016/j.pscychresns.2014.03.002  1
2014 Sachdev P, Kalaria R, O'Brien J, Skoog I, Alladi S, Black SE, Blacker D, Blazer DG, Chen C, Chui H, Ganguli M, Jellinger K, Jeste DV, Pasquier F, Paulsen J, ... ... Scheltens P, et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Disease and Associated Disorders. 28: 206-18. PMID 24632990 DOI: 10.1097/WAD.0000000000000034  1
2014 Adriaanse SM, van Dijk KR, Ossenkoppele R, Reuter M, Tolboom N, Zwan MD, Yaqub M, Boellaard R, Windhorst AD, van der Flier WM, Scheltens P, Lammertsma AA, Barkhof F, van Berckel BN. The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging. 41: 1190-8. PMID 24615466 DOI: 10.1007/s00259-014-2704-z  1
2014 van der Flier WM, Pijnenburg YA, Prins N, Lemstra AW, Bouwman FH, Teunissen CE, van Berckel BN, Stam CJ, Barkhof F, Visser PJ, van Egmond E, Scheltens P. Optimizing patient care and research: the Amsterdam Dementia Cohort. Journal of Alzheimer's Disease : Jad. 41: 313-27. PMID 24614907 DOI: 10.3233/JAD-132306  1
2014 Olde Rikkert MG, Verhey FR, Sijben JW, Bouwman FH, Dautzenberg PL, Lansink M, Sipers WM, van Asselt DZ, van Hees AM, Stevens M, Vellas B, Scheltens P. Differences in nutritional status between very mild Alzheimer's disease patients and healthy controls. Journal of Alzheimer's Disease : Jad. 41: 261-71. PMID 24614903 DOI: 10.3233/JAD-131892  1
2014 Seelen M, Visser AE, Overste DJ, Kim HJ, Palud A, Wong TH, van Swieten JC, Scheltens P, Voermans NC, Baas F, de Jong JM, van der Kooi AJ, de Visser M, Veldink JH, Taylor JP, et al. No mutations in hnRNPA1 and hnRNPA2B1 in Dutch patients with amyotrophic lateral sclerosis, frontotemporal dementia, and inclusion body myopathy. Neurobiology of Aging. 35: 1956.e9-1956.e11. PMID 24612671 DOI: 10.1016/j.neurobiolaging.2014.01.152  0.32
2014 Smits LL, Flapper M, Sistermans N, Pijnenburg YA, Scheltens P, van der Flier WM. Apraxia in mild cognitive impairment and Alzheimer's disease: validity and reliability of the Van Heugten test for apraxia. Dementia and Geriatric Cognitive Disorders. 38: 55-64. PMID 24603451 DOI: 10.1159/000358168  1
2014 Kerklaan BJ, van Berckel BN, Herholz K, Dols A, van der Flier WM, Scheltens P, Pijnenburg YA. The added value of 18-fluorodeoxyglucose-positron emission tomography in the diagnosis of the behavioral variant of frontotemporal dementia. American Journal of Alzheimer's Disease and Other Dementias. 29: 607-13. PMID 24576796 DOI: 10.1177/1533317514524811  1
2014 Del Campo M, Hoozemans JJ, Dekkers LL, Rozemuller AJ, Korth C, Müller-Schiffmann A, Scheltens P, Blankenstein MA, Jimenez CR, Veerhuis R, Teunissen CE. BRI2-BRICHOS is increased in human amyloid plaques in early stages of Alzheimer's disease. Neurobiology of Aging. 35: 1596-604. PMID 24524963 DOI: 10.1016/j.neurobiolaging.2014.01.007  1
2014 Zonneveld HI, Goos JD, Wattjes MP, Prins ND, Scheltens P, van der Flier WM, Kuijer JP, Muller M, Barkhof F. Prevalence of cortical superficial siderosis in a memory clinic population. Neurology. 82: 698-704. PMID 24477113 DOI: 10.1212/WNL.0000000000000150  1
2014 de Waal H, Stam CJ, Lansbergen MM, Wieggers RL, Kamphuis PJ, Scheltens P, Maestú F, van Straaten EC. The effect of souvenaid on functional brain network organisation in patients with mild Alzheimer's disease: a randomised controlled study. Plos One. 9: e86558. PMID 24475144 DOI: 10.1371/journal.pone.0086558  1
2014 van de Pol LA, Scheltens P. Medial temporal lobe atrophy scores translated to clinical practice: editorial comment on 'influence of age, disease onset and ApoE4 on visual medial temporal lobe atrophy cut-offs'. Journal of Internal Medicine. 275: 331-3. PMID 24330145 DOI: 10.1111/joim.12176  1
2014 Smits LL, Tijms BM, Benedictus MR, Koedam EL, Koene T, Reuling IE, Barkhof F, Scheltens P, Pijnenburg YA, Wattjes MP, van der Flier WM. Regional atrophy is associated with impairment in distinct cognitive domains in Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 10: S299-305. PMID 24210526 DOI: 10.1016/j.jalz.2013.06.007  1
2014 Harper L, Barkhof F, Scheltens P, Schott JM, Fox NC. An algorithmic approach to structural imaging in dementia. Journal of Neurology, Neurosurgery, and Psychiatry. 85: 692-8. PMID 24133287 DOI: 10.1136/jnnp-2013-306285  1
2014 Möller C, van der Flier WM, Versteeg A, Benedictus MR, Wattjes MP, Koedam EL, Scheltens P, Barkhof F, Vrenken H. Quantitative regional validation of the visual rating scale for posterior cortical atrophy. European Radiology. 24: 397-404. PMID 24092044 DOI: 10.1007/s00330-013-3025-5  1
2014 Binnewijzend MA, Adriaanse SM, Van der Flier WM, Teunissen CE, de Munck JC, Stam CJ, Scheltens P, van Berckel BN, Barkhof F, Wink AM. Brain network alterations in Alzheimer's disease measured by eigenvector centrality in fMRI are related to cognition and CSF biomarkers. Human Brain Mapping. 35: 2383-93. PMID 24039033 DOI: 10.1002/hbm.22335  1
2014 Chincarini A, Bosco P, Gemme G, Esposito M, Rei L, Squarcia S, Bellotti R, Minthon L, Frisoni G, Scheltens P, Frölich L, Soininen H, Visser PJ, Nobili F. Automatic temporal lobe atrophy assessment in prodromal AD: Data from the DESCRIPA study. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 10: 456-67. PMID 24035058 DOI: 10.1016/j.jalz.2013.05.1774  1
2014 van Rooden S, Goos JD, van Opstal AM, Versluis MJ, Webb AG, Blauw GJ, van der Flier WM, Scheltens P, Barkhof F, van Buchem MA, van der Grond J. Increased number of microinfarcts in Alzheimer disease at 7-T MR imaging. Radiology. 270: 205-11. PMID 24029643 DOI: 10.1148/radiol.13130743  1
2014 Krudop WA, Kerssens CJ, Dols A, Prins ND, Möller C, Schouws S, Barkhof F, van Berckel BN, Teunissen CE, van der Flier WM, Scheltens P, Stek ML, Pijnenburg YA. Building a new paradigm for the early recognition of behavioral variant frontotemporal dementia: Late Onset Frontal Lobe Syndrome study. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 22: 735-40. PMID 23806681 DOI: 10.1016/j.jagp.2013.02.002  1
2014 Oudega ML, van Exel E, Wattjes MP, Comijs HC, Scheltens P, Barkhof F, Eikelenboom P, de Craen AJ, Beekman AT, Stek ML. White matter hyperintensities and cognitive impairment during electroconvulsive therapy in severely depressed elderly patients. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 22: 157-66. PMID 23567440 DOI: 10.1016/j.jagp.2012.08.002  1
2014 Exalto LG, van der Flier WM, Scheltens P, Vrenken H, Biessels GJ. Dysglycemia, brain volume and vascular lesions on MRI in a memory clinic population. Journal of Diabetes and Its Complications. 28: 85-90. PMID 23352495 DOI: 10.1016/j.jdiacomp.2012.12.003  1
2014 Adriaanse SM, Sanz-Arigita EJ, Binnewijzend MA, Ossenkoppele R, Tolboom N, van Assema DM, Wink AM, Boellaard R, Yaqub M, Windhorst AD, van der Flier WM, Scheltens P, Lammertsma AA, Rombouts SA, Barkhof F, et al. Amyloid and its association with default network integrity in Alzheimer's disease. Human Brain Mapping. 35: 779-91. PMID 23238869 DOI: 10.1002/hbm.22213  1
2014 Ossenkoppele R, Booij J, Scheltens P, Van Berckel BNM. Dementia due to neurodegenerative disease: Molecular imaging findings Pet and Spect in Neurology. 185-211. DOI: 10.1007/978-3-642-54307-4_9  1
2014 Scheltens P. Memory training after a stroke provides confidence | Geheugentraining na een beroerte geeft vertrouwen Nederlands Tijdschrift Voor Geneeskunde. 158.  1
2013 Scheltens P, Twisk JW. [Medical nutrition in Alzheimer's: the trials]. Nederlands Tijdschrift Voor Geneeskunde. 157: A6721. PMID 24326116  1
2013 Shah RC, Kamphuis PJ, Leurgans S, Swinkels SH, Sadowsky CH, Bongers A, Rappaport SA, Quinn JF, Wieggers RL, Scheltens P, Bennett DA. The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer's disease. Alzheimer's Research & Therapy. 5: 59. PMID 24280255 DOI: 10.1186/alzrt224  1
2013 Prins ND, Scheltens P. Treating Alzheimer's disease with monoclonal antibodies: current status and outlook for the future. Alzheimer's Research & Therapy. 5: 56. PMID 24216217 DOI: 10.1186/alzrt220  1
2013 Sikkes SA, Pijnenburg YA, Knol DL, de Lange-de Klerk ES, Scheltens P, Uitdehaag BM. Assessment of instrumental activities of daily living in dementia: diagnostic value of the Amsterdam Instrumental Activities of Daily Living Questionnaire. Journal of Geriatric Psychiatry and Neurology. 26: 244-50. PMID 24212244 DOI: 10.1177/0891988713509139  1
2013 Tanskanen M, Kalaria RN, Notkola IL, Mäkelä M, Polvikoski T, Myllykangas L, Sulkava R, Kalimo H, Paetau A, Scheltens P, Barkhof F, van Straaten E, Erkinjuntti T. Relationships between white matter hyperintensities, cerebral amyloid angiopathy and dementia in a population-based sample of the oldest old. Current Alzheimer Research. 10: 1090-7. PMID 24156259  1
2013 Gossink F, Dols A, Kerssens CJ, Scheltens P, Stek ML, Pijnenburg YA. [The behavioural variant of frontotemporal dementia: a challenging diagnosis]. Nederlands Tijdschrift Voor Geneeskunde. 157: A6370. PMID 24128597  1
2013 Poil SS, de Haan W, van der Flier WM, Mansvelder HD, Scheltens P, Linkenkaer-Hansen K. Integrative EEG biomarkers predict progression to Alzheimer's disease at the MCI stage. Frontiers in Aging Neuroscience. 5: 58. PMID 24106478 DOI: 10.3389/fnagi.2013.00058  1
2013 Joling KJ, Bosmans JE, van Marwijk HW, van der Horst HE, Scheltens P, Vroomen JL, van Hout HP. The cost-effectiveness of a family meetings intervention to prevent depression and anxiety in family caregivers of patients with dementia: a randomized trial. Trials. 14: 305. PMID 24053631 DOI: 10.1186/1745-6215-14-305  1
2013 van Harten AC, Smits LL, Teunissen CE, Visser PJ, Koene T, Blankenstein MA, Scheltens P, van der Flier WM. Preclinical AD predicts decline in memory and executive functions in subjective complaints. Neurology. 81: 1409-16. PMID 24049134 DOI: 10.1212/WNL.0b013e3182a8418b  1
2013 Köhler S, Hamel R, Sistermans N, Koene T, Pijnenburg YA, van der Flier WM, Scheltens P, Visser PJ, Aalten P, Verhey FR, Ramakers I. Progression to dementia in memory clinic patients without dementia: a latent profile analysis. Neurology. 81: 1342-9. PMID 23997152 DOI: 10.1212/WNL.0b013e3182a82536  1
2013 Hooshmand B, Polvikoski T, Kivipelto M, Tanskanen M, Myllykangas L, Erkinjuntti T, Mäkelä M, Oinas M, Paetau A, Scheltens P, van Straaten EC, Sulkava R, Solomon A. Plasma homocysteine, Alzheimer and cerebrovascular pathology: a population-based autopsy study. Brain : a Journal of Neurology. 136: 2707-16. PMID 23983028 DOI: 10.1093/brain/awt206  1
2013 van de Glind EM, van Enst WA, van Munster BC, Olde Rikkert MG, Scheltens P, Scholten RJ, Hooft L. Pharmacological treatment of dementia: a scoping review of systematic reviews. Dementia and Geriatric Cognitive Disorders. 36: 211-28. PMID 23941762 DOI: 10.1159/000353892  1
2013 van Berckel BN, Ossenkoppele R, Tolboom N, Yaqub M, Foster-Dingley JC, Windhorst AD, Scheltens P, Lammertsma AA, Boellaard R. Longitudinal amyloid imaging using 11C-PiB: methodologic considerations. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 54: 1570-6. PMID 23940304 DOI: 10.2967/jnumed.112.113654  1
2013 van der Flier WM, Ossenkoppele R, van Berckel BN, Scheltens P. [Early diagnosis of Alzheimer disease: the role of Positron Emission Tomography (PET)]. Tijdschrift Voor Gerontologie En Geriatrie. 44: 190-1. PMID 23929236 DOI: 10.1007/s12439-013-0033-5  1
2013 Frisoni GB, Bocchetta M, Chételat G, Rabinovici GD, de Leon MJ, Kaye J, Reiman EM, Scheltens P, Barkhof F, Black SE, Brooks DJ, Carrillo MC, Fox NC, Herholz K, Nordberg A, et al. Imaging markers for Alzheimer disease: which vs how. Neurology. 81: 487-500. PMID 23897875 DOI: 10.1212/WNL.0b013e31829d86e8  1
2013 Scheltens P. Dementia: Mild cognitive impairment--amyloid and beyond. Nature Reviews. Neurology. 9: 493-5. PMID 23877645 DOI: 10.1038/nrneurol.2013.147  1
2013 Kreisel SH, Blahak C, Bäzner H, Inzitari D, Pantoni L, Poggesi A, Chabriat H, Erkinjuntti T, Fazekas F, Ferro JM, Langhorne P, O'Brien J, Scheltens P, Visser MC, Wahlund LO, et al. Deterioration of gait and balance over time: the effects of age-related white matter change--the LADIS study. Cerebrovascular Diseases (Basel, Switzerland). 35: 544-53. PMID 23838682 DOI: 10.1159/000350725  1
2013 Verwey NA, Hoozemans JJ, Korth C, van Royen MR, Prikulis I, Wouters D, Twaalfhoven HA, van Haastert ES, Schenk D, Scheltens P, Rozemuller AJ, Blankenstein MA, Veerhuis R. Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid β-peptide. Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis. 20: 179-87. PMID 23829200 DOI: 10.3109/13506129.2013.797389  1
2013 Vellas B, Carrillo MC, Sampaio C, Brashear HR, Siemers E, Hampel H, Schneider LS, Weiner M, Doody R, Khachaturian Z, Cedarbaum J, Grundman M, Broich K, Giacobini E, Dubois B, ... ... Scheltens P, et al. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 9: 438-44. PMID 23809364 DOI: 10.1016/j.jalz.2013.03.007  1
2013 Jochemsen HM, Muller M, Visseren FL, Scheltens P, Vincken KL, Mali WP, van der Graaf Y, Geerlings MI. Blood pressure and progression of brain atrophy: the SMART-MR Study. Jama Neurology. 70: 1046-53. PMID 23753860 DOI: 10.1001/jamaneurol.2013.217  1
2013 Benedictus MR, Goos JD, Binnewijzend MA, Muller M, Barkhof F, Scheltens P, Prins ND, van der Flier WM. Specific risk factors for microbleeds and white matter hyperintensities in Alzheimer's disease. Neurobiology of Aging. 34: 2488-94. PMID 23731952 DOI: 10.1016/j.neurobiolaging.2013.04.023  1
2013 Galasko D, Golde TE, Scheltens P. Progress in Alzheimer's disease research circa 2013: Is the glass half empty or half full? Alzheimer's Research & Therapy. 5: 26. PMID 23731836 DOI: 10.1186/alzrt180  1
2013 Verdelho A, Madureira S, Moleiro C, Ferro JM, O'Brien JT, Poggesi A, Pantoni L, Fazekas F, Scheltens P, Waldemar G, Wallin A, Erkinjuntti T, Inzitari D. Depressive symptoms predict cognitive decline and dementia in older people independently of cerebral white matter changes: the LADIS study. Journal of Neurology, Neurosurgery, and Psychiatry. 84: 1250-4. PMID 23715914 DOI: 10.1136/jnnp-2012-304191  1
2013 Sikkes SA, Knol DL, Pijnenburg YA, de Lange-de Klerk ES, Uitdehaag BM, Scheltens P. Validation of the Amsterdam IADL Questionnaire©, a new tool to measure instrumental activities of daily living in dementia. Neuroepidemiology. 41: 35-41. PMID 23712106 DOI: 10.1159/000346277  1
2013 Damian M, Hausner L, Jekel K, Richter M, Froelich L, Almkvist O, Boada M, Bullock R, De Deyn PP, Frisoni GB, Hampel H, Jones RW, Kehoe P, Lenoir H, Minthon L, ... ... Scheltens P, et al. Single-domain amnestic mild cognitive impairment identified by cluster analysis predicts Alzheimer's disease in the european prospective DESCRIPA study. Dementia and Geriatric Cognitive Disorders. 36: 1-19. PMID 23651945 DOI: 10.1159/000348354  1
2013 Molinuevo JL, Cummings JL, Dubois B, Scheltens P. Medical Clinics of North America. Early diagnosis and intervention in predementia Alzheimer's disease. Preface. The Medical Clinics of North America. 97: xiii-xv. PMID 23642584 DOI: 10.1016/j.mcna.2013.01.003  1
2013 Cummings JL, Dubois B, Molinuevo JL, Scheltens P. International Work Group criteria for the diagnosis of Alzheimer disease. The Medical Clinics of North America. 97: 363-8. PMID 23642575 DOI: 10.1016/j.mcna.2013.01.001  1
2013 Duits FH, Kester MI, Scheffer PG, Blankenstein MA, Scheltens P, Teunissen CE, van der Flier WM. Increase in cerebrospinal fluid F2-isoprostanes is related to cognitive decline in APOE ε4 carriers. Journal of Alzheimer's Disease : Jad. 36: 563-70. PMID 23629585 DOI: 10.3233/JAD-122227  1
2013 de Waal H, Stam CJ, de Haan W, van Straaten EC, Blankenstein MA, Scheltens P, van der Flier WM. Alzheimer's disease patients not carrying the apolipoprotein E ε4 allele show more severe slowing of oscillatory brain activity. Neurobiology of Aging. 34: 2158-63. PMID 23587637 DOI: 10.1016/j.neurobiolaging.2013.03.007  1
2013 Prins ND, van der Flier WM, Brashear HR, Knol DL, van de Pol LA, Barkhof F, Scheltens P. Predictors of progression from mild cognitive impairment to dementia in the placebo-arm of a clinical trial population. Journal of Alzheimer's Disease : Jad. 36: 79-85. PMID 23563246 DOI: 10.3233/JAD-122233  1
2013 Möller C, Vrenken H, Jiskoot L, Versteeg A, Barkhof F, Scheltens P, van der Flier WM. Different patterns of gray matter atrophy in early- and late-onset Alzheimer's disease. Neurobiology of Aging. 34: 2014-22. PMID 23561509 DOI: 10.1016/j.neurobiolaging.2013.02.013  1
2013 Tijms BM, Wink AM, de Haan W, van der Flier WM, Stam CJ, Scheltens P, Barkhof F. Alzheimer's disease: connecting findings from graph theoretical studies of brain networks. Neurobiology of Aging. 34: 2023-36. PMID 23541878 DOI: 10.1016/j.neurobiolaging.2013.02.020  1
2013 Clerx L, van Rossum IA, Burns L, Knol DL, Scheltens P, Verhey F, Aalten P, Lapuerta P, van de Pol L, van Schijndel R, de Jong R, Barkhof F, Wolz R, Rueckert D, Bocchetta M, et al. Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment. Neurobiology of Aging. 34: 2003-13. PMID 23540941 DOI: 10.1016/j.neurobiolaging.2013.02.002  1
2013 Tijms BM, Möller C, Vrenken H, Wink AM, de Haan W, van der Flier WM, Stam CJ, Scheltens P, Barkhof F. Single-subject grey matter graphs in Alzheimer's disease. Plos One. 8: e58921. PMID 23536835 DOI: 10.1371/journal.pone.0058921  1
2013 Vos SJ, van Rossum IA, Verhey F, Knol DL, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, Frisoni GB, Froelich L, Nobili F, van der Flier W, Blennow K, Wolz R, ... Scheltens P, et al. Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Neurology. 80: 1124-32. PMID 23446677 DOI: 10.1212/WNL.0b013e318288690c  1
2013 Barkhof F, Daams M, Scheltens P, Brashear HR, Arrighi HM, Bechten A, Morris K, McGovern M, Wattjes MP. An MRI rating scale for amyloid-related imaging abnormalities with edema or effusion. Ajnr. American Journal of Neuroradiology. 34: 1550-5. PMID 23436056 DOI: 10.3174/ajnr.A3475  1
2013 Jokinen H, Schmidt R, Ropele S, Fazekas F, Gouw AA, Barkhof F, Scheltens P, Madureira S, Verdelho A, Ferro JM, Wallin A, Poggesi A, Inzitari D, Pantoni L, Erkinjuntti T, et al. Diffusion changes predict cognitive and functional outcome: the LADIS study. Annals of Neurology. 73: 576-83. PMID 23423951 DOI: 10.1002/ana.23802  1
2013 Moleiro C, Madureira S, Verdelho A, Ferro JM, Poggesi A, Chabriat H, Erkinjuntti T, Fazekas F, Hennerici M, O'Brien J, Pantoni L, Salvadori E, Scheltens P, Visser MC, Wahlund LO, et al. Confirmatory factor analysis of the Neuropsychological Assessment Battery of the LADIS study: a longitudinal analysis. Journal of Clinical and Experimental Neuropsychology. 35: 269-78. PMID 23398381 DOI: 10.1080/13803395.2013.770822  1
2013 Okroglic S, Widmann CN, Urbach H, Scheltens P, Heneka MT. Clinical symptoms and risk factors in cerebral microangiopathy patients. Plos One. 8: e53455. PMID 23393549 DOI: 10.1371/journal.pone.0053455  1
2013 Prestia A, Caroli A, van der Flier WM, Ossenkoppele R, Van Berckel B, Barkhof F, Teunissen CE, Wall AE, Carter SF, Schöll M, Choo IH, Nordberg A, Scheltens P, Frisoni GB. Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology. 80: 1048-56. PMID 23390179 DOI: 10.1212/WNL.0b013e3182872830  1
2013 Vermeiren AP, Bosma H, Visser PJ, Zeegers MP, Graff C, Ewers M, Frisoni GB, Frölich L, Hampel H, Jones RW, Kehoe PG, Lenoir H, Minthon L, Nobili FM, Olde Rikkert M, ... ... Scheltens P, et al. The association between APOE ε4 and Alzheimer-type dementia among memory clinic patients is confined to those with a higher education. The DESCRIPA Study. Journal of Alzheimer's Disease : Jad. 35: 241-6. PMID 23380990 DOI: 10.3233/JAD-122182  1
2013 van der Vlies AE, Staekenborg SS, Admiraal-Behloul F, Prins ND, Barkhof F, Vrenken H, Reiber JH, Scheltens P, van der Flier WM. Associations between magnetic resonance imaging measures and neuropsychological impairment in early and late onset alzheimer's disease. Journal of Alzheimer's Disease : Jad. 35: 169-78. PMID 23364136 DOI: 10.3233/JAD-121291  1
2013 Crutch SJ, Schott JM, Rabinovici GD, Boeve BF, Cappa SF, Dickerson BC, Dubois B, Graff-Radford NR, Krolak-Salmon P, Lehmann M, Mendez MF, Pijnenburg Y, Ryan NS, Scheltens P, Shakespeare T, et al. Shining a light on posterior cortical atrophy. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 9: 463-5. PMID 23274153 DOI: 10.1016/j.jalz.2012.11.004  1
2013 Ossenkoppele R, van der Flier WM, Zwan MD, Adriaanse SF, Boellaard R, Windhorst AD, Barkhof F, Lammertsma AA, Scheltens P, van Berckel BN. Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia. Neurology. 80: 359-65. PMID 23255822 DOI: 10.1212/WNL.0b013e31827f0889  1
2013 Binnewijzend MA, Kuijer JP, Benedictus MR, van der Flier WM, Wink AM, Wattjes MP, van Berckel BN, Scheltens P, Barkhof F. Cerebral blood flow measured with 3D pseudocontinuous arterial spin-labeling MR imaging in Alzheimer disease and mild cognitive impairment: a marker for disease severity. Radiology. 267: 221-30. PMID 23238159 DOI: 10.1148/radiol.12120928  1
2013 van Harten AC, Visser PJ, Pijnenburg YA, Teunissen CE, Blankenstein MA, Scheltens P, van der Flier WM. Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 9: 481-7. PMID 23232269 DOI: 10.1016/j.jalz.2012.08.004  1
2013 Poggesi A, Gouw A, van der Flier W, Pracucci G, Chabriat H, Erkinjuntti T, Fazekas F, Ferro JM, Hennerici M, Langhorne P, O'Brien JT, Visser MC, Wahlund LO, Waldemar G, Wallin A, ... Scheltens P, et al. Cerebral white matter changes are associated with abnormalities on neurological examination in non-disabled elderly: the LADIS study. Journal of Neurology. 260: 1014-21. PMID 23180181 DOI: 10.1007/s00415-012-6748-3  1
2013 Ossenkoppele R, Prins ND, Pijnenburg YA, Lemstra AW, van der Flier WM, Adriaanse SF, Windhorst AD, Handels RL, Wolfs CA, Aalten P, Verhey FR, Verbeek MM, van Buchem MA, Hoekstra OS, Lammertsma AA, ... Scheltens P, et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 9: 414-21. PMID 23164552 DOI: 10.1016/j.jalz.2012.07.003  1
2013 Zarei M, Beckmann CF, Binnewijzend MA, Schoonheim MM, Oghabian MA, Sanz-Arigita EJ, Scheltens P, Matthews PM, Barkhof F. Functional segmentation of the hippocampus in the healthy human brain and in Alzheimer's disease. Neuroimage. 66: 28-35. PMID 23128076 DOI: 10.1016/j.neuroimage.2012.10.071  1
2013 Spies PE, Claassen JA, Peer PG, Blankenstein MA, Teunissen CE, Scheltens P, van der Flier WM, Olde Rikkert MG, Verbeek MM. A prediction model to calculate probability of Alzheimer's disease using cerebrospinal fluid biomarkers. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 9: 262-8. PMID 23123231 DOI: 10.1016/j.jalz.2012.01.010  1
2013 Jongbloed W, Kester MI, van der Flier WM, Veerhuis R, Scheltens P, Blankenstein MA, Teunissen CE. Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 9: 276-83. PMID 23110867 DOI: 10.1016/j.jalz.2012.01.004  1
2013 Ramakers IH, Verhey FR, Scheltens P, Hampel H, Soininen H, Aalten P, Rikkert MO, Verbeek MM, Spiru L, Blennow K, Trojanowski JQ, Shaw LM, Visser PJ. Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment. Psychological Medicine. 43: 911-20. PMID 22954311 DOI: 10.1017/S0033291712001870  1
2013 Koedam EL, van der Vlies AE, van der Flier WM, Verwey NA, Koene T, Scheltens P, Blankenstein MA, Pijnenburg YA. Cognitive correlates of cerebrospinal fluid biomarkers in frontotemporal dementia. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 9: 269-75. PMID 22846628 DOI: 10.1016/j.jalz.2011.12.007  1
2013 Schuitemaker A, Kropholler MA, Boellaard R, van der Flier WM, Kloet RW, van der Doef TF, Knol DL, Windhorst AD, Luurtsema G, Barkhof F, Jonker C, Lammertsma AA, Scheltens P, van Berckel BN. Microglial activation in Alzheimer's disease: an (R)-[¹¹C]PK11195 positron emission tomography study. Neurobiology of Aging. 34: 128-36. PMID 22840559 DOI: 10.1016/j.neurobiolaging.2012.04.021  1
2013 Lehmann M, Koedam EL, Barnes J, Bartlett JW, Barkhof F, Wattjes MP, Schott JM, Scheltens P, Fox NC. Visual ratings of atrophy in MCI: prediction of conversion and relationship with CSF biomarkers. Neurobiology of Aging. 34: 73-82. PMID 22516280 DOI: 10.1016/j.neurobiolaging.2012.03.010  1
2013 Zarei M, Beckmann CF, Binnewijzend MAA, Schoonheim MM, Oghabian MA, Sanz-Arigita EJ, Scheltens P, Matthews PM, Barkhof F. Corrigendum to "Functional segmentation of the hippocampus in the healthy human brain and in Alzheimer's disease" [Neuroimage 66 (2013) 28-35] Neuroimage. 83: 1109. DOI: 10.1016/j.neuroimage.2013.09.005  1
2013 Joling K, Van Marwijk H, Van Der Horst H, Scheltens P, Van De Ven P, Smit F, Appels B, Van Hout H. Family meetings for caregivers of people with dementia | Familiegesprekken voor mantelzorgers van mensen met dementie Huisarts En Wetenschap. 56: 160-164. DOI: 10.1007/s12445-013-0093-3  1
2013 Gossink F, Dols A, Kerssens CJ, Scheltens P, Stek ML, Pijnenburg YAL. The behavioural variant of frontotemporal dementia | De gedragsvariant van frontotemporale dementie Nederlands Tijdschrift Voor Geneeskunde. 157.  1
2012 Verdelho A, Madureira S, Ferro JM, Baezner H, Blahak C, Poggesi A, Hennerici M, Pantoni L, Fazekas F, Scheltens P, Waldemar G, Wallin A, Erkinjuntti T, Inzitari D. Physical activity prevents progression for cognitive impairment and vascular dementia: results from the LADIS (Leukoaraiosis and Disability) study. Stroke; a Journal of Cerebral Circulation. 43: 3331-5. PMID 23117721 DOI: 10.1161/STROKEAHA.112.661793  1
2012 Visser PJ, Vos S, van Rossum I, Scheltens P. Comparison of International Working Group criteria and National Institute on Aging-Alzheimer's Association criteria for Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 8: 560-3. PMID 23102126 DOI: 10.1016/j.jalz.2011.10.008  1
2012 Sikkes SA, de Lange-de Klerk ES, Pijnenburg YA, Gillissen F, Romkes R, Knol DL, Uitdehaag BM, Scheltens P. A new informant-based questionnaire for instrumental activities of daily living in dementia. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 8: 536-43. PMID 23102123 DOI: 10.1016/j.jalz.2011.08.006  1
2012 van Assema DM, Lubberink M, Rizzu P, van Swieten JC, Schuit RC, Eriksson J, Scheltens P, Koepp M, Lammertsma AA, van Berckel BN. Blood-brain barrier P-glycoprotein function in healthy subjects and Alzheimer's disease patients: effect of polymorphisms in the ABCB1 gene. Ejnmmi Research. 2: 57. PMID 23067778 DOI: 10.1186/2191-219X-2-57  1
2012 van Rossum IA, Vos SJ, Burns L, Knol DL, Scheltens P, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, L'italien G, van der Flier WM, Teunissen CE, Blennow K, Barkhof F, et al. Injury markers predict time to dementia in subjects with MCI and amyloid pathology. Neurology. 79: 1809-16. PMID 23019259 DOI: 10.1212/WNL.0b013e3182704056  1
2012 Pleizier CM, van der Vlies AE, Koedam E, Koene T, Barkhof F, van der Flier WM, Scheltens P, Pijnenburg Y. Episodic memory and the medial temporal lobe: not all it seems. Evidence from the temporal variants of frontotemporal dementia. Journal of Neurology, Neurosurgery, and Psychiatry. 83: 1145-8. PMID 22933816 DOI: 10.1136/jnnp-2012-302437  1
2012 de Haan W, Mott K, van Straaten EC, Scheltens P, Stam CJ. Activity dependent degeneration explains hub vulnerability in Alzheimer's disease. Plos Computational Biology. 8: e1002582. PMID 22915996 DOI: 10.1371/journal.pcbi.1002582  1
2012 Filippi M, Agosta F, Barkhof F, Dubois B, Fox NC, Frisoni GB, Jack CR, Johannsen P, Miller BL, Nestor PJ, Scheltens P, Sorbi S, Teipel S, Thompson PM, Wahlund LO, et al. EFNS task force: the use of neuroimaging in the diagnosis of dementia. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 19: e131-40, 1487-501. PMID 22900895 DOI: 10.1111/j.1468-1331.2012.03859.x  1
2012 Hooghiemstra AM, Eggermont LH, Scheltens P, van der Flier WM, Bakker J, de Greef MH, Koppe PA, Scherder EJ. Study protocol: EXERcise and cognition in sedentary adults with early-ONset dementia (EXERCISE-ON). Bmc Neurology. 12: 75. PMID 22897903 DOI: 10.1186/1471-2377-12-75  0.84
2012 Sorbi S, Hort J, Erkinjuntti T, Fladby T, Gainotti G, Gurvit H, Nacmias B, Pasquier F, Popescu BO, Rektorova I, Religa D, Rusina R, Rossor M, Schmidt R, Stefanova E, ... ... Scheltens P, et al. EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 19: 1159-79. PMID 22891773 DOI: 10.1111/j.1468-1331.2012.03784.x  1
2012 Handels RL, Aalten P, Wolfs CA, OldeRikkert M, Scheltens P, Visser PJ, Joore MA, Severens JL, Verhey FR. Diagnostic and economic evaluation of new biomarkers for Alzheimer's disease: the research protocol of a prospective cohort study. Bmc Neurology. 12: 72. PMID 22883691 DOI: 10.1186/1471-2377-12-72  1
2012 Schmidt R, Berghold A, Jokinen H, Gouw AA, van der Flier WM, Barkhof F, Scheltens P, Petrovic K, Madureira S, Verdelho A, Ferro JM, Waldemar G, Wallin A, Wahlund LO, Poggesi A, et al. White matter lesion progression in LADIS: frequency, clinical effects, and sample size calculations. Stroke; a Journal of Cerebral Circulation. 43: 2643-7. PMID 22879094 DOI: 10.1161/STROKEAHA.112.662593  1
2012 van der Vlies AE, Goos JD, Barkhof F, Scheltens P, van der Flier WM. Microbleeds do not affect rate of cognitive decline in Alzheimer disease. Neurology. 79: 763-9. PMID 22875093 DOI: 10.1212/WNL.0b013e3182661f91  1
2012 Most EI, Scheltens P, Van Someren EJ. Increased skin temperature in Alzheimer's disease is associated with sleepiness. Journal of Neural Transmission (Vienna, Austria : 1996). 119: 1185-94. PMID 22828713 DOI: 10.1007/s00702-012-0864-1  1
2012 van Straaten EC, de Haan W, de Waal H, Scheltens P, van der Flier WM, Barkhof F, Koene T, Stam CJ. Disturbed oscillatory brain dynamics in subcortical ischemic vascular dementia. Bmc Neuroscience. 13: 85. PMID 22827860 DOI: 10.1186/1471-2202-13-85  1
2012 Scheltens P, Twisk JW, Blesa R, Scarpini E, von Arnim CA, Bongers A, Harrison J, Swinkels SH, Stam CJ, de Waal H, Wurtman RJ, Wieggers RL, Vellas B, Kamphuis PJ. Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. Journal of Alzheimer's Disease : Jad. 31: 225-36. PMID 22766770 DOI: 10.3233/JAD-2012-121189  1
2012 Vellas B, Hausner L, Frölich L, Cantet C, Gardette V, Reynish E, Gillette S, Agüera-Morales E, Auriacombe S, Boada M, Bullock R, Byrne J, Camus V, Cherubini A, Eriksdotter-Jönhagen M, ... ... Scheltens P, et al. Progression of Alzheimer disease in Europe: data from the European ICTUS study. Current Alzheimer Research. 9: 902-12. PMID 22742853 DOI: 10.2174/156720512803251066  1
2012 Hooghiemstra AM, Eggermont LH, Scheltens P, van der Flier WM, Scherder EJ. Exercise and early-onset Alzheimer's disease: theoretical considerations. Dementia and Geriatric Cognitive Disorders Extra. 2: 132-45. PMID 22590474  0.84
2012 van Assema DM, Goos JD, van der Flier WM, Lubberink M, Boellaard R, Windhorst AD, Scheltens P, Lammertsma AA, van Berckel BN. No evidence for additional blood-brain barrier P-glycoprotein dysfunction in Alzheimer's disease patients with microbleeds. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 32: 1468-71. PMID 22588188 DOI: 10.1038/jcbfm.2012.64  1
2012 Scheltens P, van de Pol L. Impact commentaries. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. Journal of Neurology, Neurosurgery, and Psychiatry. 83: 1038-40. PMID 22566596 DOI: 10.1136/jnnp-2012-302562  1
2012 Ossenkoppele R, Zwan MD, Tolboom N, van Assema DM, Adriaanse SF, Kloet RW, Boellaard R, Windhorst AD, Barkhof F, Lammertsma AA, Scheltens P, van der Flier WM, van Berckel BN. Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement. Brain : a Journal of Neurology. 135: 2115-25. PMID 22556189 DOI: 10.1093/brain/aws113  1
2012 de Haan W, van der Flier WM, Wang H, Van Mieghem PF, Scheltens P, Stam CJ. Disruption of functional brain networks in Alzheimer's disease: what can we learn from graph spectral analysis of resting-state magnetoencephalography? Brain Connectivity. 2: 45-55. PMID 22480296 DOI: 10.1089/brain.2011.0043  0.84
2012 van Assema DM, Lubberink M, Boellaard R, Schuit RC, Windhorst AD, Scheltens P, Lammertsma AA, van Berckel BN. P-glycoprotein function at the blood-brain barrier: effects of age and gender. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 14: 771-6. PMID 22476967 DOI: 10.1007/s11307-012-0556-0  1
2012 Ossenkoppele R, Tolboom N, Foster-Dingley JC, Adriaanse SF, Boellaard R, Yaqub M, Windhorst AD, Barkhof F, Lammertsma AA, Scheltens P, van der Flier WM, van Berckel BN. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. European Journal of Nuclear Medicine and Molecular Imaging. 39: 990-1000. PMID 22441582 DOI: 10.1007/s00259-012-2102-3  1
2012 Smits LL, Pijnenburg YA, Koedam EL, van der Vlies AE, Reuling IE, Koene T, Teunissen CE, Scheltens P, van der Flier WM. Early onset Alzheimer's disease is associated with a distinct neuropsychological profile. Journal of Alzheimer's Disease : Jad. 30: 101-8. PMID 22366769 DOI: 10.3233/JAD-2012-111934  0.84
2012 Mattsson N, Rosén E, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek MM, Olde Rikkert M, Tsolaki M, ... ... Scheltens P, et al. Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology. 78: 468-76. PMID 22302554 DOI: 10.1212/WNL.0b013e3182477eed  1
2012 Wilkinson D, Fox NC, Barkhof F, Phul R, Lemming O, Scheltens P. Memantine and brain atrophy in Alzheimer's disease: a 1-year randomized controlled trial. Journal of Alzheimer's Disease : Jad. 29: 459-69. PMID 22269160 DOI: 10.3233/JAD-2011-111616  1
2012 Vos S, van Rossum I, Burns L, Knol D, Scheltens P, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, Handels R, L'Italien G, van der Flier W, Aalten P, Teunissen C, et al. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Neurobiology of Aging. 33: 2272-81. PMID 22264648 DOI: 10.1016/j.neurobiolaging.2011.12.017  1
2012 van Assema DM, Lubberink M, Boellaard R, Schuit RC, Windhorst AD, Scheltens P, van Berckel BN, Lammertsma AA. Reproducibility of quantitative (R)-[11C]verapamil studies. Ejnmmi Research. 2: 1. PMID 22251281 DOI: 10.1186/2191-219X-2-1  1
2012 van Rossum IA, Visser PJ, Knol DL, van der Flier WM, Teunissen CE, Barkhof F, Blankenstein MA, Scheltens P. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 29: 319-27. PMID 22233766 DOI: 10.3233/JAD-2011-111694  1
2012 Scheltens P, Goos JD. Dementia in 2011: Microbleeds in dementia--singing a different ARIA. Nature Reviews. Neurology. 8: 68-70. PMID 22231195 DOI: 10.1038/nrneurol.2011.222  0.8
2012 Wouters H, Appels B, van der Flier WM, van Campen J, Klein M, Zwinderman AH, Schmand B, van Gool WA, Scheltens P, Lindeboom R. Improving the accuracy and precision of cognitive testing in mild dementia. Journal of the International Neuropsychological Society : Jins. 18: 314-22. PMID 22206624 DOI: 10.1017/S1355617711001755  1
2012 Schoonenboom NS, Reesink FE, Verwey NA, Kester MI, Teunissen CE, van de Ven PM, Pijnenburg YA, Blankenstein MA, Rozemuller AJ, Scheltens P, van der Flier WM. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology. 78: 47-54. PMID 22170879 DOI: 10.1212/WNL.0b013e31823ed0f0  1
2012 de Haan W, van der Flier WM, Koene T, Smits LL, Scheltens P, Stam CJ. Disrupted modular brain dynamics reflect cognitive dysfunction in Alzheimer's disease. Neuroimage. 59: 3085-93. PMID 22154957 DOI: 10.1016/j.neuroimage.2011.11.055  0.84
2012 van Assema DM, Lubberink M, Bauer M, van der Flier WM, Schuit RC, Windhorst AD, Comans EF, Hoetjes NJ, Tolboom N, Langer O, Müller M, Scheltens P, Lammertsma AA, van Berckel BN. Blood-brain barrier P-glycoprotein function in Alzheimer's disease. Brain : a Journal of Neurology. 135: 181-9. PMID 22120145 DOI: 10.1093/brain/awr298  1
2012 Goos JD, Teunissen CE, Veerhuis R, Verwey NA, Barkhof F, Blankenstein MA, Scheltens P, van der Flier WM. Microbleeds relate to altered amyloid-β metabolism in Alzheimer's disease. Neurobiology of Aging. 33: 1011.e1-9. PMID 22118945 DOI: 10.1016/j.neurobiolaging.2011.10.026  1
2012 de Waal H, Stam CJ, de Haan W, van Straaten EC, Scheltens P, van der Flier WM. Young Alzheimer patients show distinct regional changes of oscillatory brain dynamics. Neurobiology of Aging. 33: 1008.e25-31. PMID 22118944 DOI: 10.1016/j.neurobiolaging.2011.10.013  0.84
2012 Kester MI, van der Flier WM, Visser A, Blankenstein MA, Scheltens P, Oudejans CB. Decreased mRNA expression of CCL5 [RANTES] in Alzheimer's disease blood samples. Clinical Chemistry and Laboratory Medicine : Cclm / Fescc. 50: 61-5. PMID 21942811 DOI: 10.1515/CCLM.2011.731  1
2012 Binnewijzend MA, Schoonheim MM, Sanz-Arigita E, Wink AM, van der Flier WM, Tolboom N, Adriaanse SM, Damoiseaux JS, Scheltens P, van Berckel BN, Barkhof F. Resting-state fMRI changes in Alzheimer's disease and mild cognitive impairment. Neurobiology of Aging. 33: 2018-28. PMID 21862179 DOI: 10.1016/j.neurobiolaging.2011.07.003  1
2012 Kester MI, Scheffer PG, Koel-Simmelink MJ, Twaalfhoven H, Verwey NA, Veerhuis R, Twisk JW, Bouwman FH, Blankenstein MA, Scheltens P, Teunissen C, van der Flier WM. Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers. Neurobiology of Aging. 33: 1591-8. PMID 21741127 DOI: 10.1016/j.neurobiolaging.2011.05.013  1
2012 Lehmann M, Koedam EL, Barnes J, Bartlett JW, Ryan NS, Pijnenburg YA, Barkhof F, Wattjes MP, Scheltens P, Fox NC. Posterior cerebral atrophy in the absence of medial temporal lobe atrophy in pathologically-confirmed Alzheimer's disease. Neurobiology of Aging. 33: 627.e1-627.e12. PMID 21596458 DOI: 10.1016/j.neurobiolaging.2011.04.003  1
2012 Ewers M, Walsh C, Trojanowski JQ, Shaw LM, Petersen RC, Jack CR, Feldman HH, Bokde AL, Alexander GE, Scheltens P, Vellas B, Dubois B, Weiner M, Hampel H. Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiology of Aging. 33: 1203-14. PMID 21159408 DOI: 10.1016/j.neurobiolaging.2010.10.019  1
2012 Schuitemaker A, van der Doef TF, Boellaard R, van der Flier WM, Yaqub M, Windhorst AD, Barkhof F, Jonker C, Kloet RW, Lammertsma AA, Scheltens P, van Berckel BN. Microglial activation in healthy aging. Neurobiology of Aging. 33: 1067-72. PMID 21051106 DOI: 10.1016/j.neurobiolaging.2010.09.016  1
2012 Jacobs HI, Visser PJ, Van Boxtel MP, Frisoni GB, Tsolaki M, Papapostolou P, Nobili F, Wahlund LO, Minthon L, Frölich L, Hampel H, Soininen H, van de Pol L, Scheltens P, Tan FE, et al. Association between white matter hyperintensities and executive decline in mild cognitive impairment is network dependent. Neurobiology of Aging. 33: 201.e1-8. PMID 20739101 DOI: 10.1016/j.neurobiolaging.2010.07.015  1
2012 Hort J, Popescu BO, Scheltens P. Lessons learned in eastern europe Global Clinical Trials Playbook. 99-103. DOI: 10.1016/B978-0-12-415787-3.00009-6  1
2011 Sikkes SA, Knol DL, van den Berg MT, de Lange-de Klerk ES, Scheltens P, Klein M, Pijnenburg YA, Uitdehaag BM. An informant questionnaire for detecting Alzheimer's disease: are some items better than others? Journal of the International Neuropsychological Society : Jins. 17: 674-81. PMID 22882809 DOI: 10.1017/S1355617711000543  0.6
Show low-probability matches.